

# Research Toward a Cure July 16, 2025

**Table 1. Current Clinical Trials**

| Trial                                                                                                                                                                                   | Trial Registry Identifier(s)                          | Country location(s) | Sponsor(s)                                       | Phase    | Estimated End Date/Interim Results                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|---------------------|--------------------------------------------------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>ADOPTIVE IMMUNOTHERAPY</b>                                                                                                                                                           |                                                       |                     |                                                  |          |                                                                                                                                                                                                                                |
| <b>AutoRESIST:</b> HIV antigen-specific T-cells targeting conserved epitopes for treatment of HIV-associated lymphoma                                                                   | <a href="#">NCT04975698</a><br>(closed to enrollment) | United States       | Catherine Bollard, Children's Research Institute | Phase II | June 2026                                                                                                                                                                                                                      |
| <b>AlloRESIST:</b> Evaluate the safety, immunologic, and virologic responses of donor derived HIV-specific T-cells in HIV+ individuals following allogeneic bone marrow transplantation | <a href="#">NCT04248192</a><br>(closed to enrollment) | United States       | Catherine Bollard, Children's Research Institute | Phase I  | April 2026                                                                                                                                                                                                                     |
| <b>ANALYTICAL TREATMENT INTERRUPTION</b>                                                                                                                                                |                                                       |                     |                                                  |          |                                                                                                                                                                                                                                |
| Assessment of HIV remission in early treated individuals with the MHC B35/53Bw4TTC2 genotype                                                                                            | <a href="#">NCT05482854</a>                           | France              | ANRS                                             | N/A      | July 2025                                                                                                                                                                                                                      |
| <b>SCOPE-ATI</b>                                                                                                                                                                        | <a href="#">NCT04359186</a>                           | United States       | UCSF                                             | N/A      | June 2026<br><a href="#">APCS. 2025 Feb 20</a><br><a href="#">AIDS Behav. 2024 Sep 17.</a><br>CROI 2024, Abstracts <a href="#">446</a> , <a href="#">482</a><br><a href="#">Strategies for an HIV Cure 2023, Abstract PP64</a> |
| Imaging and biopsy of people with HIV undergoing ATI                                                                                                                                    | <a href="#">NCT05419024</a>                           | United States       | National Cancer Institute (NCI)                  | Phase II | August 2026<br>CROI 2024, <a href="#">Abstract 502</a><br><a href="#">Strategies for an HIV Cure 2023, Abstract PP41</a><br><a href="#">Front Med. 2022 Aug 22;9:979756.</a>                                                   |

# Research Toward a Cure July 16, 2025

**Table 1. Current Clinical Trials (Cont.)**

| Trial                                                                   | Trial Registry Identifier(s)                                         | Country location(s) | Manufacturer/ Sponsor(s)                                                           | Phase       | Estimated End Date/Interim Results                                                                          |
|-------------------------------------------------------------------------|----------------------------------------------------------------------|---------------------|------------------------------------------------------------------------------------|-------------|-------------------------------------------------------------------------------------------------------------|
| <b>ANTI-<math>\alpha</math>4<math>\beta</math>7 INTEGRIN ANTIBODIES</b> |                                                                      |                     |                                                                                    |             |                                                                                                             |
| <b>vedolizumab</b> (anti- $\alpha$ 4 $\beta$ 7 integrin antibody)       | <a href="#">NCT03147859</a>                                          | Canada              | Ottawa Hospital Research Institute                                                 | Phase II    | December 2023<br><a href="#">BMJ Open. 2020; 10(10):e041359.</a><br>CROI 2019, <a href="#">Abstract 393</a> |
| <b>ANTI-CMV THERAPY</b>                                                 |                                                                      |                     |                                                                                    |             |                                                                                                             |
| <b>letermovir</b> (Prevymis)                                            | <a href="#">NCT06626555</a><br>(not yet open for enrollment)         | United Kingdom      | University College, London                                                         | Phase II    | March 2026                                                                                                  |
| <b>ANTI-INFLAMMATORY</b>                                                |                                                                      |                     |                                                                                    |             |                                                                                                             |
| Fecal Microbiota Transplantation (FMT)                                  | <a href="#">NCT06022406</a>                                          | Canada              | Jean-Pierre Routy, McGill University Health Centre                                 | Phase II    | September 2025                                                                                              |
| <b>ANTIRETROVIRAL THERAPY</b>                                           |                                                                      |                     |                                                                                    |             |                                                                                                             |
| Administration of high doses of antiretrovirals                         | <a href="#">NCT06640192</a>                                          | Spain               | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Phase II    | January 2027                                                                                                |
| <b>BCL-2 ANTAGONISTS</b>                                                |                                                                      |                     |                                                                                    |             |                                                                                                             |
| <b>venetoclax</b>                                                       | <a href="#">NCT05668026</a>                                          | Australia, Denmark  | University of Aarhus                                                               | Phase I/IIb | December 2026                                                                                               |
| <b>BISPECIFIC T-CELL ENGAGERS</b>                                       |                                                                      |                     |                                                                                    |             |                                                                                                             |
| <b>GS-8588</b>                                                          | No clinicaltrials.gov entry, <a href="#">listed on UPenn website</a> | United States       | Gilead Sciences                                                                    | Phase I     | N/A                                                                                                         |

# Research Toward a Cure July 16, 2025

**Table 1. Current Clinical Trials (Cont.)**

| Trial                                                      | Trial Registry Identifier(s)                       | Country location(s)            | Manufacturer/ Sponsor(s)                                               | Phase      | Estimated End Date/Interim Results                                                                                                                                                                                                                                                 |
|------------------------------------------------------------|----------------------------------------------------|--------------------------------|------------------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>BROADLY NEUTRALIZING ANTIBODIES</b>                     |                                                    |                                |                                                                        |            |                                                                                                                                                                                                                                                                                    |
| <b>10-1074-LS + 3BNC117-LS</b> in primary HIV infection    | <a href="#">NCT04319367</a>                        | United Kingdom                 | Imperial College London                                                | Phase II   | July 2027<br>CROI 2025, Abstracts <a href="#">107</a> , <a href="#">505</a> , <a href="#">506</a><br><a href="#">IAS HIV Cure &amp; Immunotherapy Forum 2023</a><br>HIV Persistence Workshop 2022, <a href="#">Abstracts OP 7.2, PP 8.11 (slides) Trials. 2022 Apr 5;23(1):263</a> |
| <b>3BNC117-LS + 10-1074-LS</b>                             | <a href="#">NCT06205602</a><br>(enrollment paused) | Botswana, South Africa         | AIDS Clinical Trials Group                                             | Phase II   | February 2029                                                                                                                                                                                                                                                                      |
| <b>3BNC117-LS + 10-1074-LS</b>                             | <a href="#">NCT05300035</a>                        | France                         | French National Agency for Research on AIDS and Viral Hepatitis (ANRS) | Phase II   | December 2028                                                                                                                                                                                                                                                                      |
| <b>VRC07-523LS + PGT121.414.LS</b>                         | <a href="#">NCT05719441</a><br>(enrollment paused) | Brazil, Peru, United States    | NIAID                                                                  | Phase II   | September 2028                                                                                                                                                                                                                                                                     |
| <b>Tatelo Plus:</b> PGDM1400LS, VRC07-523LS, PGT121.414.LS | <a href="#">NCT06508749</a>                        | Botswana                       | NIAID                                                                  | Phase I/II | February 2028                                                                                                                                                                                                                                                                      |
| <b>3BNC117-LS-J + 10-1074-LS-J</b>                         | <a href="#">NCT06031272</a><br>(enrollment paused) | Botswana, Malawi, South Africa | ACTG                                                                   | Phase I    | June 2026                                                                                                                                                                                                                                                                          |
| <b>3BNC117-LS + 10-1074-LS</b>                             | <a href="#">NCT05612178</a>                        | United States                  | NIAID                                                                  | Phase I    | December 2025                                                                                                                                                                                                                                                                      |

# Research Toward a Cure July 16, 2025

**Table 1. Current Clinical Trials (Cont.)**

| Trial                                                                                                           | Trial Registry Identifier(s)                                 | Country location(s)         | Manufacturer/ Sponsor(s)                                            | Phase    | Estimated End Date/Interim Results                                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-----------------------------|---------------------------------------------------------------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>BROADLY NEUTRALIZING ANTIBODIES (Cont.)</b>                                                                  |                                                              |                             |                                                                     |          |                                                                                                                                                                                                                                                |
| <b>AAV8-VRC07</b> (broadly neutralizing antibody delivered by AAV vector)                                       | <a href="#">NCT03374202</a><br>(closed to enrollment)        | United States               | NIAID                                                               | Phase I  | August 2026<br><a href="#">Nat Med. 28(5):1022-1030.</a><br>CROI 2022, <a href="#">Abstract 498</a><br>CROI 2021, <a href="#">Abstract 160</a> , <a href="#">Webcast</a><br>CROI 2020, <a href="#">Abstract 41LB</a> , <a href="#">Webcast</a> |
| <b>CAP256V2LS + VRC07-523LS</b>                                                                                 | <a href="#">PACTR202309578224660</a>                         | South Africa                | Centre for the AIDS Programme of Research in South Africa (CAPRISA) | Phase I  | October 2025                                                                                                                                                                                                                                   |
| <b>VH4527079</b> bispecific antibody                                                                            | <a href="#">NCT06652958</a>                                  | United States               | ViiV Healthcare                                                     | Phase I  | February 2027                                                                                                                                                                                                                                  |
| <b>VRC07-523LS + PGT121.414.LS</b>                                                                              | <a href="#">NCT06987318</a><br>(not yet open for enrollment) | Brazil, Peru, United States | NIAID                                                               | Phase I  | May 2028                                                                                                                                                                                                                                       |
| <b>CD4 ATTACHMENT INHIBITORS</b>                                                                                |                                                              |                             |                                                                     |          |                                                                                                                                                                                                                                                |
| <b>UB-421</b> (antibody inhibitor of HIV binding to CD4 receptors)                                              | <a href="#">NCT04404049</a><br>(not yet open for enrollment) | China                       | UBP Greater China (Shanghai) Co., Ltd                               | Phase II | June 2025                                                                                                                                                                                                                                      |
| <b>COMBINATIONS</b>                                                                                             |                                                              |                             |                                                                     |          |                                                                                                                                                                                                                                                |
| PD-1 inhibitor <b>sindilizumab</b> combined with <b>chidamide</b>                                               | <a href="#">NCT06902038</a><br>(not yet open for enrollment) | China                       | Jun Chen, MD                                                        | N/A      | December 2027                                                                                                                                                                                                                                  |
| <b>maraviroc</b> , <b>dolutegravir</b> , <b>dendritic cell vaccine</b> , <b>auranofin</b> , <b>nicotinamide</b> | <a href="#">NCT06805656</a><br>(not yet open for enrollment) | Brazil                      | Federal University of São Paulo                                     | N/A      | December 2027                                                                                                                                                                                                                                  |
| <b>AbVax</b> : ChAdOx1.tHIVconsv1 + HIVconsv62, MVA.tHIVconsv4, <b>teropavimab</b> , <b>zinlirvimab</b>         | <a href="#">NCT07054931</a><br>(not yet open for enrollment) | United Kingdom              | University of Oxford                                                | Phase II | June 2028                                                                                                                                                                                                                                      |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 1. Current Clinical Trials (Cont.)**

| Trial                                                                                                                                                                                                                       | Trial Registry Identifier(s)                                 | Country location(s)                                                                                                             | Manufacturer/ Sponsor(s)              | Phase       | Estimated End Date/Interim Results                                                                                                                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>COMBINATIONS (Cont.)</b>                                                                                                                                                                                                 |                                                              |                                                                                                                                 |                                       |             |                                                                                                                                                                                                                                                             |
| <b>budigalimab</b> (anti-PD-1 antibody) +/- <b>trosunilimab</b> (anti- $\alpha_4\beta_7$ integrin antibody)                                                                                                                 | <a href="#">NCT06032546</a><br>(closed to enrollment)        | Belgium, Brazil, Canada, France, Germany, Italy, Japan, Poland, Puerto Rico, South Africa, Spain, United Kingdom, United States | AbbVie                                | Phase II    | March 2027                                                                                                                                                                                                                                                  |
| <b>UB-421 + chidamide</b> (antibody inhibitor of HIV binding to CD4 receptors + HDAC inhibitor)                                                                                                                             | <a href="#">NCT04985890</a><br>(not yet open for enrollment) | Taiwan                                                                                                                          | UBP Greater China (Shanghai) Co., Ltd | Phase II    | December 2027                                                                                                                                                                                                                                               |
| <b>Ad26.Mos4.HIV, MVA-BN-HIV, PGT121, PGDM1400, VRC07-523LS</b>                                                                                                                                                             | <a href="#">NCT04983030</a><br>(closed to enrollment)        | United States                                                                                                                   | Boris Juelg, MD PhD                   | Phase I/IIa | April 2026                                                                                                                                                                                                                                                  |
| <b>ChAdOx1.tHIVconsV1, HIVconsV62, MVA.tHIVconsV3, tHIVconsV4, 3BNC117-LS, 10-1074-LS, vesatolimod</b>                                                                                                                      | <a href="#">NCT06071767</a><br>(enrollment paused)           | Brazil, United States                                                                                                           | NIAID                                 | Phase I/IIa | August 2029                                                                                                                                                                                                                                                 |
| <b>IMPAACT P1115 v2.0:</b> Very early intensive treatment of infants with HIV to achieve remission (ART +/- VRC01)                                                                                                          | <a href="#">NCT02140255</a>                                  | Argentina, Brazil, Haiti, Kenya, Malawi, Puerto Rico, South Africa, Tanzania, Thailand, Uganda, United States, Zambia, Zimbabwe | IMPAACT                               | Phase I/II  | December 2031<br>CROI 2024, Abstracts <a href="#">184</a> , <a href="#">954</a><br><a href="#">Lancet HIV. S2352-3018(23)00236-9.</a><br><a href="#">Strat. HIV Cure 2023, Abstract PP05</a><br>CROI 2022, <a href="#">Abstract 31</a>                      |
| Therapeutic conserved element DNA vaccine ( <b>IL-12 adjuvanted p24CE</b> ), MVA vaccine boost ( <b>MVA/HIV62B</b> ), TLR9 agonist ( <b>lefitolimod</b> ), broadly neutralizing antibodies ( <b>VRC07-523LS + 10-1074</b> ) | <a href="#">NCT04357821</a><br>(closed to enrollment)        | United States                                                                                                                   | UCSF                                  | Phase I/II  | December 2025<br><a href="#">ARHR 2025 Feb 5.</a><br>CROI 2024, Abstracts <a href="#">446</a> , <a href="#">618</a><br><a href="#">HRCP 25(1):2312318</a><br><a href="#">Strat. HIV Cure 2023, Abstract PP66</a><br>CROI 2023, <a href="#">Abstract 435</a> |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 1. Current Clinical Trials (Cont.)**

| Trial                                                                                                      | Trial Registry Identifier(s)                                 | Country location(s)   | Manufacturer/ Sponsor(s)                                             | Phase       | Estimated End Date/Interim Results                                                                  |
|------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-----------------------|----------------------------------------------------------------------|-------------|-----------------------------------------------------------------------------------------------------|
| <b>COMBINATIONS (Cont.)</b>                                                                                |                                                              |                       |                                                                      |             |                                                                                                     |
| <b>HVRRICANE:</b> HIVIS DNA + MVA-CMDR vaccines +/- TLR4 agonist                                           | <a href="#">NCT04301154</a><br>(closed to enrollment)        | South Africa          | PENTA Foundation                                                     | Phase I     | February 2025<br>CROI 2025, <a href="#">Abstract 407</a><br>CROI 2024, <a href="#">Abstract 408</a> |
| <b>N6-LS</b> (VH3810109) +/- <b>fostemsavir</b>                                                            | <a href="#">NCT07053384</a><br>(not yet open for enrollment) | United States, Europe | ViiV Healthcare                                                      | Phase I     | March 2028                                                                                          |
| <b>N-803</b> (recombinant human super agonist interleukin-15 complex) +/- <b>VRC07-523LS + 10-1074</b>     | <a href="#">NCT04340596</a><br>(closed to enrollment)        | United States         | NIAID                                                                | Phase I     | December 2026                                                                                       |
| <b>N-803, 3BNC117-LS, 10-1074-LS</b>                                                                       | <a href="#">NCT05245292</a><br>(closed to enrollment)        | United States         | Rockefeller University                                               | Phase I     | December 2025<br><a href="#">IAS 2025, Abstract OAA0202</a>                                         |
| <b>VRC07-523LS, PGDM1400LS, ChAdOx1.tHIVconsV1, ChAdOx1.HIVconsV62, MVA.tHIVconsV4, A244d11 gp120/ALFQ</b> | <a href="#">NCT06484335</a><br>(not yet open for enrollment) | Thailand              | Henry M. Jackson Foundation for the Advancement of Military Medicine | Phase I     | August 2027<br>CROI 2025, <a href="#">Abstract 508</a>                                              |
| <b>CYTOKINES</b>                                                                                           |                                                              |                       |                                                                      |             |                                                                                                     |
| <b>N-803</b> in acute HIV infection                                                                        | <a href="#">NCT04505501</a><br>(closed to enrollment)        | Thailand              | Thai Red Cross AIDS Research Centre                                  | Phase II    | June 2025<br>CROI 2025, Abstracts <a href="#">444</a> , <a href="#">512</a>                         |
| <b>GENE THERAPIES</b>                                                                                      |                                                              |                       |                                                                      |             |                                                                                                     |
| <b>LVgp120duoCAR-T cells</b>                                                                               | <a href="#">NCT04648046</a>                                  | United States         | Steven Deeks, UCSF                                                   | Phase I/IIa | December 2029                                                                                       |
| <b>Cal-1:</b> Dual anti-HIV gene transfer construct                                                        | <a href="#">NCT02390297</a><br>(closed to enrollment)        | United States         | Calimmune                                                            | Phase I/II  | October 2031<br>CROI 2020, <a href="#">Abstract 338</a>                                             |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 1. Current Clinical Trials (Cont.)**

| Trial                                                                                                    | Trial Registry Identifier(s)                                 | Country location(s) | Manufacturer/ Sponsor(s)                          | Phase      | Estimated End Date/Interim Results                                                                  |
|----------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|---------------------|---------------------------------------------------|------------|-----------------------------------------------------------------------------------------------------|
| <b>GENE THERAPIES (Cont.)</b>                                                                            |                                                              |                     |                                                   |            |                                                                                                     |
| An ATI study to evaluate the impact of <b>AGT103-T</b> to suppress HIV replication in the absence of ART | <a href="#">NCT05540964</a><br>(enrolling by invitation)     | United States       | American Gene Technologies International Inc.     | Phase I    | July 2025<br><a href="#">IAS 2025, Abstract OAA0506LB</a><br><a href="#">Front Med. 11:1342476.</a> |
| <b>CD4 CAR + SB-728mR</b> modified T cells                                                               | <a href="#">NCT03617198</a><br>(closed to enrollment)        | United States       | University of Pennsylvania                        | Phase I    | December 2027<br><a href="#">CROI 2022 (James L. Riley)</a>                                         |
| Chimeric Antigen Receptor (CAR)-T cell therapy                                                           | <a href="#">NCT03240328</a>                                  | China               | Guangzhou 8th People's Hospital                   | Phase I    | December 2030<br><a href="#">JCI. 2021;150211</a>                                                   |
| <b>CMV-specific HIV-CAR T Cells</b>                                                                      | <a href="#">NCT06252402</a>                                  | United States       | City of Hope Medical Center                       | Phase I    | December 2026                                                                                       |
| <b>EBT-101</b> (long-term follow-up study)                                                               | <a href="#">NCT05143307</a><br>(enrolling by invitation)     | United States       | Excision BioTherapeutics                          | Phase I    | April 2037                                                                                          |
| <b>HIV-CAR-T</b> : Efficacy and safety study of CAR-T Cells for functional cure                          | <a href="#">NCT06880380</a><br>(not yet open for enrollment) | China               | Institute of Hematology & Blood Diseases Hospital | Phase I    | July 2026                                                                                           |
| Long-term follow-up of study participants treated with <b>AGT103-T</b>                                   | <a href="#">NCT05529342</a><br>(enrolling by invitation)     | United States       | American Gene Technologies International Inc.     | Phase I    | September 2038                                                                                      |
| <b>SB-728mR-HSPC</b> (autologous hematopoietic stem/progenitor cells modified at the CCR5 gene)          | <a href="#">NCT02500849</a><br>(closed to enrollment)        | United States       | City of Hope Medical Center                       | Phase I    | August 2025                                                                                         |
| <b>GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS</b>                                               |                                                              |                     |                                                   |            |                                                                                                     |
| Stem cells gene-modified with CCR5 shRNA/TRIM5alpha/TAR decoy                                            | <a href="#">NCT02797470</a><br>(closed to enrollment)        | United States       | AIDS Malignancy Consortium                        | Phase I/II | March 2036<br>CROI 2025, <a href="#">Abstract 538</a>                                               |
| Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ)                         | <a href="#">NCT02337985</a><br>(closed to enrollment)        | United States       | City of Hope Medical Center                       | Phase I    | October 2025                                                                                        |
| Stem cells gene-modified to encode rHIV7-shI-TAR-CCR5RZ + busulfan                                       | <a href="#">NCT01961063</a><br>(closed to enrollment)        | United States       | City of Hope Medical Center                       | Phase I    | August 2025                                                                                         |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 1. Current Clinical Trials (Cont.)**

| Trial                                                                                         | Trial Registry Identifier(s)                                 | Country location(s)  | Manufacturer/ Sponsor(s)                               | Phase           | Estimated End Date/Interim Results                                                                      |
|-----------------------------------------------------------------------------------------------|--------------------------------------------------------------|----------------------|--------------------------------------------------------|-----------------|---------------------------------------------------------------------------------------------------------|
| <b>IMAGING STUDIES</b>                                                                        |                                                              |                      |                                                        |                 |                                                                                                         |
| Imaging immune activation in HIV by PET-MR                                                    | <a href="#">NCT03684655</a>                                  | United States        | University of California, San Francisco                | Phase I         | November 2025<br>CROI 2024, <a href="#">Abstract 105</a>                                                |
| Radiolabeled VRC01                                                                            | <a href="#">NCT03729752</a>                                  | United States        | University of California, San Francisco                | Phase I         | December 2026<br><a href="#">Nat Commun. 2022;13(1):1219.</a><br>CROI 2020, <a href="#">Abstract 72</a> |
| <b>IMMUNE CHECKPOINT INHIBITORS</b>                                                           |                                                              |                      |                                                        |                 |                                                                                                         |
| <b>NIVO-LD:</b> Low dose <b>nivolumab</b> in adults living with HIV on antiretroviral therapy | <a href="#">NCT05187429</a>                                  | Australia, Singapore | University of Melbourne                                | Phase I/II      | January 2026<br>HIV Persistence 2024, <a href="#">Abstract 7.1</a>                                      |
| <b>IMMUNOMODULATORS</b>                                                                       |                                                              |                      |                                                        |                 |                                                                                                         |
| <b>lenalidomide, adenosylmethionine</b>                                                       | <a href="#">NCT05598580</a>                                  | China                | First Affiliated Hospital of Zhejiang University       | Phase IV        | November 2024                                                                                           |
| <b>PEACH:</b> Pomalidomide as an immune-enhancing agent for the control of HIV                | <a href="#">NCT06660498</a>                                  | Australia, Denmark   | University of Aarhus                                   | Phase I/IIb     | March 2026                                                                                              |
| <b>JANUS KINASE INHIBITORS</b>                                                                |                                                              |                      |                                                        |                 |                                                                                                         |
| <b>baricitinib</b>                                                                            | <a href="#">NCT05452564</a>                                  | United States        | Emory University                                       | Phase II        | January 2028                                                                                            |
| <b>baricitinib</b>                                                                            | <a href="#">NCT07028385</a><br>(not yet open for enrollment) | <b>Spain</b>         | <b>Fundación FLS de Lucha Contra el Sida</b>           | <b>Phase II</b> | <b>April 2026</b>                                                                                       |
| <b>LATENCY-REVERSING AGENTS</b>                                                               |                                                              |                      |                                                        |                 |                                                                                                         |
| <b>lauric acid</b>                                                                            | <a href="#">NCT05687565</a>                                  | Spain                | Hospital Universitari Vall d'Hebron Research Institute | N/A             | December 2025                                                                                           |
| <b>panobinostat, lenalidomide + pyrimethamine</b>                                             | <a href="#">NCT06240520</a><br>(not yet open for enrollment) | Netherlands          | Erasmus Medical Center                                 | Phase I/II      | October 2025                                                                                            |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 1. Current Clinical Trials (Cont.)**

| Trial                                                                                                                     | Trial Registry Identifier(s)                                                   | Country location(s)            | Manufacturer/ Sponsor(s)            | Phase      | Estimated End Date/Interim Results                                                           |
|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------|-------------------------------------|------------|----------------------------------------------------------------------------------------------|
| <b>LATENCY-REVERSING AGENTS (Cont.)</b>                                                                                   |                                                                                |                                |                                     |            |                                                                                              |
| <b>topiramate</b>                                                                                                         | <a href="#">NCT06282783</a><br>(not yet open for enrollment)                   | Netherlands                    | Erasmus Medical Center              | Phase I/II | August 2025                                                                                  |
| <b>arsenic trioxide</b>                                                                                                   | <a href="#">NCT03980665</a>                                                    | China                          | Guangzhou 8th People's Hospital     | Phase I    | December 2025                                                                                |
| <b>decitabine, romidepsin</b>                                                                                             | <a href="#">NCT05230368</a>                                                    | France                         | ANRS                                | Phase I    | April 2026                                                                                   |
| <b>STEM CELL TRANSPLANTATION</b>                                                                                          |                                                                                |                                |                                     |            |                                                                                              |
| Analytical treatment interruption in PWHIV post-allogeneic stem cell transplantation from a CCR5 delta32 homozygous donor | <a href="#">NCT06582797</a><br>(not yet open for enrollment)                   | United States                  | University of Kansas Medical Center | N/A        | September 2034                                                                               |
| <b>TARGETED ACTIVATOR OF CELL KILL (TACK) MOLECULES</b>                                                                   |                                                                                |                                |                                     |            |                                                                                              |
| <b>Efavirenz</b> T cell activator of cell killing study                                                                   | <a href="#">NCT06823596</a>                                                    | Canada                         | University of Toronto               | N/A        | September 2026                                                                               |
| <b>MK-4646</b>                                                                                                            | <a href="#">NCT07042945</a><br>(not yet open for enrollment)                   | N/A                            | Merck Sharp & Dohme LLC             | Phase I    | April 2026                                                                                   |
| <b>T-CELL RECEPTOR-BASED BISPECIFICS</b>                                                                                  |                                                                                |                                |                                     |            |                                                                                              |
| <b>IMC-M113V</b> in HLA-A*02:01 positive people                                                                           | <a href="#">2021-002008-11</a>                                                 | Belgium, Spain, United Kingdom | Immunocore                          | Phase I/II | CROI 2025, <a href="#">Abstract 104</a>                                                      |
| <b>THERAPEUTIC VACCINES</b>                                                                                               |                                                                                |                                |                                     |            |                                                                                              |
| <b>BELIEVE</b> : BCG vaccination effect on latent reservoir size in treated HIV-1 infection                               | <a href="#">NCT05004038</a><br>(closed to enrollment)                          | Switzerland                    | University of Zurich                | Phase IIa  | January 2024                                                                                 |
| <b>GS-1966/GS-1144</b> HIV vaccine regimens                                                                               | No clinicaltrials.gov entry, <a href="#">#7 on Midway Research Center list</a> | United States                  | Gilead Sciences                     | Phase Ib   | N/A<br>CROI 2025, <a href="#">Abstract 144</a><br>HIV Glasgow, <a href="#">Abstract P211</a> |
| <b>HB-502/HB-501</b> (arenavirus vaccine vectors)                                                                         | <a href="#">NCT06430905</a><br>(closed to enrollment)                          | United States                  | Hookipa Biotech GmbH                | Phase Ib   | November 2025                                                                                |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 1. Current Clinical Trials (Cont.)**

| Trial                                                                                                                                             | Trial Registry Identifier(s)                                 | Country location(s)    | Manufacturer/ Sponsor(s)                        | Phase    | Estimated End Date/Interim Results                                                                                                                                                                                                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|------------------------|-------------------------------------------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>THERAPEUTIC VACCINES (Cont.)</b>                                                                                                               |                                                              |                        |                                                 |          |                                                                                                                                                                                                                                                                                                                                                    |
| <b>426c.Mod.Core-C4b, 3M-052-AF + Alum</b><br><i>(*primarily focused on preventive HIV vaccine development but may also assist cure research)</i> | <a href="#">NCT06006546</a>                                  | United States          | NIAID, HIV Vaccine Trials Network               | Phase I  | December 2025                                                                                                                                                                                                                                                                                                                                      |
| <b>CH505 TF chTrimer</b> vaccine                                                                                                                  | <a href="#">NCT06680479</a>                                  | United States          | NIAID                                           | Phase I  | August 2027                                                                                                                                                                                                                                                                                                                                        |
| <b>GRADHIVNE1</b> (Gorilla adenovirus vaccine vector)                                                                                             | <a href="#">NCT06617091</a><br>(not yet open for enrollment) | South Africa, Zimbabwe | IAVI                                            | Phase I  | December 2026                                                                                                                                                                                                                                                                                                                                      |
| <b>ICVAX</b> : PD-1-enhanced HIV DNA vaccine                                                                                                      | <a href="#">NCT06253533</a><br>(closed to enrollment)        | China                  | Shenzhen Immuno Cure Biomedical Company Limited | Phase I  | June 2025<br>AIDS 2024, <a href="#">Abstract TUPEA024</a><br><a href="#">IAS HIV Cure &amp; Immunotherapy Forum 2023</a>                                                                                                                                                                                                                           |
| <b>NETI</b> : Trimer 4571 therapeutic vaccination                                                                                                 | <a href="#">NCT04985760</a><br>(closed to enrollment)        | United States          | NIAID                                           | Phase I  | November 2025                                                                                                                                                                                                                                                                                                                                      |
| <b>TREATMENT INTENSIFICATION/EARLY TREATMENT</b>                                                                                                  |                                                              |                        |                                                 |          |                                                                                                                                                                                                                                                                                                                                                    |
| <b>DGVTAf</b> : Immediate initiation of antiretroviral therapy during "hyperacute" HIV infection                                                  | <a href="#">NCT02656511</a><br>(closed to enrollment)        | United States          | UCSF                                            | Phase IV | May 2028<br>CROI 2025, <a href="#">Abstract 413</a><br><a href="#">J Virol. e0143124</a><br><a href="#">Nat Commun. 15(1):9966.</a><br><a href="#">J Clin Invest. 2024 Apr 23:e176673.</a><br>CROI 2024, Abstracts <a href="#">468</a> , <a href="#">508</a><br>IAS 2023, <a href="#">Abstract 2167</a><br>CROI 2023, <a href="#">Abstract 305</a> |

# Research Toward a Cure July 16, 2025

**Table 1. Current Clinical Trials (Cont.)**

| Trial                                                                       | Trial Registry Identifier(s)                                 | Country location(s)                                     | Manufacturer/ Sponsor(s)                           | Phase        | Estimated End Date/Interim Results                                                                                                                                                                                                                                                                                                                             |
|-----------------------------------------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)</b>                    |                                                              |                                                         |                                                    |              |                                                                                                                                                                                                                                                                                                                                                                |
| <b>AAHIV:</b> Antiretroviral therapy for acute HIV infection                | <a href="#">NCT00796263</a>                                  | Thailand                                                | South East Asia Research Collaboration with Hawaii | Phase III    | June 2033<br><a href="#">See supplemental references page</a>                                                                                                                                                                                                                                                                                                  |
| <b>EIT:</b> Early infant HIV treatment in Botswana                          | <a href="#">NCT02369406</a><br>(closed to enrollment)        | Botswana                                                | Harvard School of Public Health                    | Phase II/III | June 2029<br><a href="#">JAIDS 2022 Dec 12</a><br>CROI 2022, <a href="#">Abstract 712</a><br><a href="#">Clin Infect Dis. 2021 ciab143</a><br><a href="#">Clin Infect Dis. 2020 Jan 12.</a><br><a href="#">Sci Transl Med. 2019 Nov 27;11(520). pii: eaax7350</a><br>CROI 2019, <a href="#">Poster abstract 826</a><br>CROI 2018, <a href="#">Abstract 136</a> |
| Codivir in addition to standard antiretroviral treatment                    | <a href="#">NCT06676410</a>                                  | Brazil                                                  | Code Pharma                                        | Phase II     | December 2024                                                                                                                                                                                                                                                                                                                                                  |
| <b>EARLIER:</b> Early ART to limit infection and establishment of reservoir | <a href="#">NCT02859558</a><br>(closed to enrollment)        | Brazil, Malawi, Peru, Thailand, United States, Zimbabwe | AIDS Clinical Trials Group                         | Phase II     | April 2025<br><a href="#">AIDS. 2024 Mar 14.</a><br><a href="#">Clin Infect Dis. 2021 Aug 2;73(3):e643-e651</a>                                                                                                                                                                                                                                                |
| Gammora plus antiretroviral treatment                                       | <a href="#">NCT06799650</a>                                  | Brazil                                                  | Federal University of São Paulo                    | Phase II     | March 2025                                                                                                                                                                                                                                                                                                                                                     |
| <b>Lenacapavir</b> intensification to disrupt HIV reservoirs                | <a href="#">NCT06819176</a><br>(not yet open for enrollment) | United States                                           | NIAID                                              | Phase I      | January 2029                                                                                                                                                                                                                                                                                                                                                   |

# Research Toward a Cure July 16, 2025

**Table 1. Current Clinical Trials (Cont.)**

| Trial                             | Trial Registry Identifier(s) | Country location(s) | Manufacturer/ Sponsor(s)                                              | Phase    | Estimated End Date/Interim Results |
|-----------------------------------|------------------------------|---------------------|-----------------------------------------------------------------------|----------|------------------------------------|
| <b>TYROSINE KINASE INHIBITORS</b> |                              |                     |                                                                       |          |                                    |
| <b>dasatinib</b>                  | <a href="#">NCT05527418</a>  | Spain               | Eva Bonfill, Institut d'Investigacions Biomèdiques August Pi i Sunyer | Phase II | June 2026                          |
| <b>dasatinib</b>                  | <a href="#">NCT05780073</a>  | Spain               | Fundació Institut Germans Trias i Pujol                               | Phase II | March 2025                         |

# Research Toward a Cure July 16, 2025

**Table 2. Current Observational Studies**

| Trial                                                                                                                                                                                                                             | Trial Registry Identifier(s)                                 | Country location(s) | Manufacturer/ Sponsor(s)                | Phase | Estimated End Date/Interim Results                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|---------------------|-----------------------------------------|-------|-----------------------------------------------------------------------------------------------------------------------------|
| Accurate staging of immuno-virological dynamics during acute HIV infection (ACS)                                                                                                                                                  | <a href="#">NCT03449706</a>                                  | Belgium             | University Hospital, Ghent              | N/A   | January 2028                                                                                                                |
| Analytical treatment interruption after combination bNAb therapy                                                                                                                                                                  | <a href="#">NCT06908083</a><br>(enrolling by invitation)     | United States       | NIAID                                   | N/A   | June 2028                                                                                                                   |
| Analytic treatment interruption (ATI) to assess HIV cure                                                                                                                                                                          | <a href="#">NCT02437526</a><br>(enrolling by invitation)     | United States       | Mayo Clinic                             | N/A   | May 2035<br><a href="#">PLoS Med. 2017 Nov 28;14(11):e1002461.</a>                                                          |
| <b>ANRS CO24 OncoVIHAC:</b> Immune checkpoint inhibitors in HIV+ individuals with cancers                                                                                                                                         | <a href="#">NCT03354936</a>                                  | France              | Inserm-ANRS                             | N/A   | June 2022<br><a href="#">J Immunother Cancer. 12(8):e009728. Cells. 2022 Mar 17;11(6):1015. AIDS 2020, Abstract OAB0203</a> |
| <b>APRIL:</b> Analysis of the persistence, reservoir and HIV latency                                                                                                                                                              | <a href="#">NCT05752318</a>                                  | France              | University Hospital, Strasbourg, France | N/A   | February 2027<br>CROI 2025, <a href="#">Abstract 138 Pathog Immun. 8(2):92-114.</a>                                         |
| <b>ARCH:</b> Analysis of the reservoir in individuals controlling HIV infection                                                                                                                                                   | <a href="#">NCT06016114</a><br>(not yet open for enrollment) | Belgium             | Sponsor University Hospital, Ghent      | N/A   | October 2028                                                                                                                |
| <b>ATGALIG-HIV:</b> Study of autophagy and the effects of GALIG gene products in HIV-1+ patients on antiretroviral therapy since primary infection, chronic phase, or never treated                                               | <a href="#">NCT04160455</a>                                  | France              | Centre Hospitalier Régional d'Orléans   | N/A   | November 2039                                                                                                               |
| <b>BICTEVOIR:</b> A study to determine the cartography of virologic reservoir related to antiretroviral concentrations in HIV-1+ patients on first line treatment containing bictegravir, emtricitabine and tenofovir alafenamide | <a href="#">NCT05222945</a>                                  | France              | ANRS                                    | N/A   | October 2025                                                                                                                |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 2. Current Observational Studies (Cont.)**

| Trial                                                                                                         | Trial Registry Identifier(s)                                          | Country location(s) | Manufacturer/ Sponsor(s)                              | Phase | Estimated End Date/Interim Results                                                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|---------------------|-------------------------------------------------------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Characterization of acute and recent HIV-1 infections in Zurich: a long-term observational study              | <a href="#">NCT00537966</a>                                           | Switzerland         | University of Zurich                                  | N/A   | December 2028<br><a href="#">JID. 2024 Dec 11</a><br>AIDS 2024, <a href="#">Abstract OAA0204</a><br><a href="#">Microorganisms. 12(2):302</a><br>CROI 2023, <a href="#">Abstract 387</a> |
| <b>CHRONO</b> : A prospective cohort for ex vivo cure studies with chronic HIV+ patients in the Netherlands   | <a href="#">NCT04888754</a><br>(closed to enrollment)                 | Netherlands         | Erasmus Medical Center                                | N/A   | January 2034                                                                                                                                                                             |
| <b>CODEX</b> (the “Extreme” cohort, ANRS CO21)                                                                | <a href="#">NCT01520844</a>                                           | France              | Inserm-ANRS                                           | N/A   | September 2023<br><a href="#">See supplemental references page</a>                                                                                                                       |
| Comparing immune activation and HIV reservoir size between PWHIV on tenofovir-containing versus NRTI-free ART | <a href="#">NCT05584397</a><br>(enrolling by invitation)              | United States       | University of Washington                              | N/A   | December 2025                                                                                                                                                                            |
| Developing a functional cure for HIV disease: Clinical specimen collection from individuals with HIV          | <a href="#">NCT03215004</a><br>(closed to enrollment)                 | United States       | American Gene Technologies International Inc.         | N/A   | February 2021                                                                                                                                                                            |
| Establish and characterize an acute HIV infection cohort in a high-risk population                            | <a href="#">NCT00796146</a>                                           | Thailand            | SE Asia Research Collaboration with Hawaii            | N/A   | July 2033<br><a href="#">See supplemental references page</a>                                                                                                                            |
| Evaluation of the role of HIV-1 Tat protein and anti-Tat immune response in HIV reservoir (ISS OBS T-005)     | <a href="#">NCT04263207</a><br>(suspended)                            | Italy               | Barbara Ensoli, MD, PhD, Istituto Superiore di Sanità | N/A   | June 2025                                                                                                                                                                                |
| <b>EX VIVO</b> : Ex vivo characterization and targeting of the latent to cure HIV                             | <a href="#">NCT05215704</a>                                           | Netherlands         | Erasmus Medical Center                                | N/A   | December 2030                                                                                                                                                                            |
| <b>FRESH</b> (Females rising through education, support, and health)                                          | <a href="#">Ragon Institute webpage</a> (no clinicaltrials.gov entry) | South Africa        | Ragon Institute of MGH, MIT and Harvard               | N/A   | N/A<br><a href="#">See supplemental references page</a>                                                                                                                                  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 2. Current Observational Studies (Cont.)**

| Trial                                                                                                                                                                                 | Trial Registry Identifier(s)                                  | Country location(s) | Manufacturer/ Sponsor(s)   | Phase | Estimated End Date/Interim Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------|----------------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>HI-ART:</b> Optimising cohorts for HIV cure interventions                                                                                                                          | <a href="#">NCT05852301</a>                                   | Australia           | Bayside Health             | N/A   | December 2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>HIV-Mercuri:</b> HIV study on measuring the reservoir on cellular level to cure infection                                                                                          | <a href="#">NCT04305665</a>                                   | Belgium             | University Hospital, Ghent | N/A   | December 2025<br><a href="#">Nat Com 16(1):2173</a><br><a href="#">Clin Chem. 2025 Jan 3;71(1):203-214.</a>                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>iCHIP:</b> Effect of immune checkpoint inhibitors on HIV persistence                                                                                                               | <a href="#">hivcure.com.au</a> (no registry entry)            | Australia           | University of Melbourne    | N/A   | N/A<br><a href="#">JIM 113198</a><br><a href="#">AIDS. 2021 Apr 15.</a><br>CROI 2020, <a href="#">Abstract 334</a>                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>IciStem:</b> Collaborative project to guide and investigate the potential for HIV cure in HIV+ patients requiring allogeneic stem cell transplantation for hematological disorders | <a href="#">IciStem website</a> (no clinicaltrials.gov entry) | International       | amfAR                      | N/A   | N/A<br><a href="#">Nat Med. 2024 Sep 2.</a><br><a href="#">Lancet HIV. 11(6):e389-e405.</a><br>IAS 2023, <a href="#">Abstract OALBA0504</a><br><a href="#">Viruses. 2022 Sep 17;14(9):2069.</a><br>CROI 2020, <a href="#">Abstract 339</a> , <a href="#">Abstract 348LB</a><br><a href="#">Lancet HIV 2020 Mar 9.</a><br>HIV Persistence 2019, <a href="#">Abstract OP 4.5</a><br><a href="#">Nature. 2019 Apr;568(7751):244-248.</a><br>CROI 2019, <a href="#">Poster abstract 394</a><br><a href="#">Ann Intern Med. 2018;169(10):674-683.</a> |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 2. Current Observational Studies (Cont.)**

| Trial                                                                                                                                                        | Trial Registry Identifier(s)                                 | Country location(s)                                                                                       | Manufacturer/ Sponsor(s)                           | Phase | Estimated End Date/Interim Results                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|----------------------------------------------------|-------|--------------------------------------------------------------------|
| Identification and quantification of HIV CNS latency biomarkers                                                                                              | <a href="#">NCT02989285</a>                                  | Australia                                                                                                 | St Vincent's Hospital, Sydney                      | N/A   | December 2020<br><a href="#">PNAS 119(48): e2210584119.</a>        |
| Immuno-virological evaluation of persons living with HIV (PLWH)                                                                                              | <a href="#">NCT05973825</a><br>(not yet open for enrollment) | Belgium                                                                                                   | University Hospital, Ghent                         | N/A   | July 2029                                                          |
| Investigation of the impact of inducible, replication-competent latent HIV-1 as an impediment to HIV/AIDS cure in the context of sustained viral suppression | <a href="#">NCT04938518</a>                                  | Kenya                                                                                                     | Kenya Medical Research Institute                   | N/A   | April 2022                                                         |
| <b>LAMIVIH:</b> Evolution of HIV reservoir, inflammation, and microbiota footprint of PLWH switching to long-acting injectable treatment                     | <a href="#">NCT05303337</a>                                  | France                                                                                                    | Hôpital Européen Marseille                         | N/A   | March 2024                                                         |
| Long-term clinical, immunologic, and virologic profiles of children who received early treatment for HIV                                                     | <a href="#">NCT05154513</a><br>(closed to enrollment)        | Botswana, Brazil, Haiti, Kenya, Malawi, South Africa, Tanzania, Thailand, Uganda, United States, Zimbabwe | IMPAACT                                            | N/A   | November 2025                                                      |
| <b>NOVA:</b> Netherlands cohort study on acute HIV infection                                                                                                 | <a href="#">NCT05728996</a>                                  | Netherlands                                                                                               | Prof. Jan Prins                                    | N/A   | August 2028                                                        |
| Observational post-intervention controller (PIC) destination cohort                                                                                          | <a href="#">NCT05985642</a>                                  | International                                                                                             | AIDS Clinical Trials Group                         | N/A   | September 2029                                                     |
| <b>PediacamNEG:</b> Negative serology in children with HIV treated early with ART                                                                            | <a href="#">NCT06302933</a>                                  | Cameroon                                                                                                  | Inserm-ANRS                                        | N/A   | August 2025                                                        |
| Post analytic treatment interruption study                                                                                                                   | <a href="#">NCT02761200</a>                                  | Thailand                                                                                                  | South East Asia Research Collaboration with Hawaii | N/A   | March 2031                                                         |
| <b>PRIMO</b> (ANRS CO6): Primary infection cohort                                                                                                            | <a href="#">NCT03148964</a>                                  | France                                                                                                    | Inserm-ANRS                                        | N/A   | September 2025<br><a href="#">See supplemental references page</a> |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 2. Current Observational Studies (Cont.)**

| Trial                                                                                                                                                            | Trial Registry Identifier(s)                          | Country location(s) | Manufacturer/ Sponsor(s)                   | Phase | Estimated End Date/Interim Results                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|---------------------|--------------------------------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>RESERVIH32:</b> Bioclinical evaluation of two biomarkers of aviremic HIV-1 in CD4 T cells of adults undergoing treatment                                      | <a href="#">NCT03940521</a>                           | France              | Centre Hospitalier Universitaire de Nîmes  | N/A   | September 2026                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Saturne-HIV:</b> Sequential analysis before and after treatment initiation to unravel the role of naturally occurring extracellular vesicles in HIV infection | <a href="#">NCT04653610</a>                           | Belgium             | University Hospital, Ghent                 | N/A   | January 2027                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>TatLat:</b> Development of a new family of HIV latency regulators (LRAs) targeting the Tat viral protein                                                      | <a href="#">NCT06441123</a>                           | France              | University Hospital, Montpellier           | N/A   | February 2027                                                                                                                                                                                                                                                                                                                                                                                                            |
| The Gemini Study: Safety and survival of genetically modified white blood cells in HIV+ twins                                                                    | <a href="#">NCT04799483</a><br>(closed to enrollment) | United States       | NIAID                                      | N/A   | January 2030                                                                                                                                                                                                                                                                                                                                                                                                             |
| The Last Gift Study (for people with HIV and less than 6 months life expectancy due to terminal illness)                                                         | <a href="#">UCSD study website</a>                    | United States       | University of California, San Diego (UCSD) | N/A   | N/A<br><a href="#">Strategies for an HIV Cure 2023, Abstracts PP22 &amp; PP73</a><br><a href="#">J Virus Erad. 2023 Jun 5;9(2):100328.</a><br><a href="#">Curr HIV/AIDS Rep. 2022 Oct 19;1-14.</a><br><a href="#">J Med Ethics. 2022 Jun 22</a><br><a href="#">PLoS One. 2021 May 7;16(5):e0250882.</a><br><a href="#">J Clin Invest. 2020 Jan 7</a><br>HIV Persistence Workshop 2019, <a href="#">Abstract PP 5.7.5</a> |

# Research Toward a Cure July 16, 2025

**Table 2. Current Observational Studies (Cont.)**

| Trial                                                                                        | Trial Registry Identifier(s)                              | Country location(s) | Manufacturer/ Sponsor(s)                                        | Phase | Estimated End Date/Interim Results |
|----------------------------------------------------------------------------------------------|-----------------------------------------------------------|---------------------|-----------------------------------------------------------------|-------|------------------------------------|
| The role of the gastrointestinal-associated lymphoid tissue in the cure of HIV infection     | <a href="#">NCT05652088</a>                               | United States       | Icahn School of Medicine at Mount Sinai                         | N/A   | June 2026                          |
| The use of leukapheresis to support HIV pathogenesis studies                                 | <a href="#">NCT01161199</a>                               | United States       | University of California, San Francisco                         | N/A   | July 2033                          |
| Thinking and memory problems in people with HIV                                              | <a href="#">NCT01875588</a>                               | United States       | National Institute of Neurological Disorders and Stroke (NINDS) | N/A   | February 2037                      |
| <b>TRESAX:</b> T follicular helper reservoir in axillary lymph nodes study                   | <a href="#">hivcure.com.au</a> (no registry entry)        | Australia           | Kirby Institute                                                 | N/A   | N/A                                |
| <b>ViPer:</b> Role of viral reservoir, immune activation and depletion in persistent viremia | <a href="#">NCT07015164</a> (not yet open for enrollment) | France              | Assistance Publique - Hôpitaux de Paris                         | N/A   | September 2026                     |

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies**

| Trial                                                                                        | Trial Registry Identifier(s)        | Manufacturer/ Sponsor(s)                                                      | Phase      | Published/Presented Data                                                                                                                                            |
|----------------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------------------------------------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>ADOPTIVE IMMUNOTHERAPY</b>                                                                |                                     |                                                                               |            |                                                                                                                                                                     |
| Early ART in combination with autologous HIV-specific cytotoxic T lymphocyte (CTL) infusion  | <a href="#">NCT02231281</a>         | Yongtao Sun, MD, PhD, Tangdu Hospital, the Fourth Military Medical University | Phase III  | N/A                                                                                                                                                                 |
| Reconstitution of HIV-specific immunity against HIV                                          | <a href="#">NCT02563509</a>         | Guangzhou 8th People's Hospital                                               | Phase I/II | N/A                                                                                                                                                                 |
| HIV-specific memory CD8 T cells adoptive immunotherapy                                       | <a href="#">ChiCTR-ICR-15005775</a> | Beijing You'an Hospital, Capital Medical University                           | Phase I    | <a href="#">Front Immunol. 2019 Mar 18;10:437</a>                                                                                                                   |
| <b>HST-NEETs</b> : HIV-1 specific T-cells for HIV+ individuals                               | <a href="#">NCT03485963</a>         | Children's Research Institute                                                 | Phase I    | <a href="#">Nat Comm 16(1):4510</a><br>2024 ASGCT, <a href="#">Abstract 1908</a><br>2022 ASH Meeting, <a href="#">Abstract 3339</a>                                 |
| <b>HXTC</b> : HIV 1 antigen expanded specific T cell therapy                                 | <a href="#">NCT02208167</a>         | University of North Carolina, Chapel Hill                                     | Phase I    | <a href="#">Mol Ther. 2018 Oct 3;26(10):2496-2506.</a>                                                                                                              |
| <b>ANALYTICAL TREATMENT INTERRUPTION</b>                                                     |                                     |                                                                               |            |                                                                                                                                                                     |
| <b>TESOVIR</b> : Tracking and exploring the source of viral rebound                          | <a href="#">NCT03117985</a>         | Centre Hospitalier Régional d'Orléans                                         | N/A        | Terminated (no interesting results)                                                                                                                                 |
| <b>ANTIBODIES</b>                                                                            |                                     |                                                                               |            |                                                                                                                                                                     |
| <b>CHERUB 001</b> : IVIG in primary HIV infection                                            | No clinicaltrials.gov entry         | CHERUB                                                                        | N/A        | <a href="#">HIV Med. 2017 Jul 18.</a>                                                                                                                               |
| <b>VRC01</b> (analytical treatment interruption in HVTN 703/HPTN 081 AMP trial participants) | <a href="#">NCT04860323</a>         | HIV Vaccine Trials Network                                                    | N/A        | <a href="#">JIAS. 28(6):e26495.</a>                                                                                                                                 |
| <b>VRC01</b> (analytical treatment interruption in HVTN 704/HPTN 085 AMP trial participants) | <a href="#">NCT04801758</a>         | HIV Vaccine Trials Network                                                    | N/A        | HIVR4P 2024, <a href="#">Abstract OA0605</a>                                                                                                                        |
| <b>GSK3810109A</b> (broadly neutralizing antibody formerly named N6-LS)                      | <a href="#">NCT04871113</a>         | Viiv Healthcare                                                               | Phase IIa  | EACS 2023, Abstracts <a href="#">PS8.05</a> & <a href="#">eP.A.099</a><br>CROI 2023, <a href="#">Abstract 520</a><br>HIV Glasgow 2022, <a href="#">Abstract O34</a> |
| <b>3BNC117</b> (broadly neutralizing monoclonal antibody)                                    | <a href="#">NCT02446847</a>         | Rockefeller University                                                        | Phase II   | <a href="#">Nature. 2016 Jul 28; 535(7613):556–560</a>                                                                                                              |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                      | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                      | Phase       | Published/Presented Data                                                                                                                                                                                                                             |
|----------------------------------------------------------------------------|------------------------------|---------------------------------------------------------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>ANTIBODIES (Cont.)</b>                                                  |                              |                                                               |             |                                                                                                                                                                                                                                                      |
| <b>3BNC117</b>                                                             | <a href="#">NCT02588586</a>  | Rockefeller University                                        | Phase II    | <a href="#">J Exp Med. 215(9):2311-2324.</a>                                                                                                                                                                                                         |
| <b>UB-421</b> (antibody inhibitor of HIV binding to CD4 receptors)         | <a href="#">NCT03743376</a>  | United BioPharma                                              | Phase II    | N/A                                                                                                                                                                                                                                                  |
| <b>UB-421</b>                                                              | <a href="#">NCT02369146</a>  | United BioPharma                                              | Phase II    | <a href="#">N Engl J Med. 2019;380(16):1535-45</a>                                                                                                                                                                                                   |
| <b>vedolizumab</b> (anti- $\alpha_4\beta_7$ integrin antibody)             | <a href="#">NCT03577782</a>  | Hospitales Universitarios Virgen del Rocío                    | Phase II    | <a href="#">JCI Insight. e182312.</a><br>CROI 2022, <a href="#">Abstract 359</a><br>XI Congreso Nacional GeSIDA, Abstract PO-48 ( <a href="#">video</a> )                                                                                            |
| <b>VRC01</b> (broadly neutralizing monoclonal antibody)                    | <a href="#">NCT02664415</a>  | National Institute of Allergy and Infectious Diseases (NIAID) | Phase II    | <a href="#">CID. 73(7):e1885-92.</a><br><a href="#">J Clin Invest. 130(6):3299-3304.</a><br><a href="#">Lancet HIV. 2019 May;6(5):e297-e306.</a><br>IAS 2017, Abstract <a href="#">TUAB0106LB</a> ( <a href="#">slides</a> , <a href="#">video</a> ) |
| <b>PGT121 + VRC07-523LS +/- PGDM1400</b> (broadly neutralizing antibodies) | <a href="#">NCT03721510</a>  | International AIDS Vaccine Initiative                         | Phase I/IIa | <a href="#">Nat Med. 2024 Sep 12.</a><br>CROI 2024, Abstracts <a href="#">121</a> , <a href="#">483</a>                                                                                                                                              |
| <b>VRC01</b> (broadly neutralizing antibody) in infants                    | <a href="#">NCT03208231</a>  | NIAID                                                         | Phase I/II  | AIDS 2022, <a href="#">Abstract QALBB0102</a>                                                                                                                                                                                                        |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                | Trial Registry Identifier(s)                        | Manufacturer/ Sponsor(s) | Phase      | Published/Presented Data                                                                                                                                                                                                                                                                           |
|--------------------------------------------------------------------------------------|-----------------------------------------------------|--------------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>ANTIBODIES (Cont.)</b>                                                            |                                                     |                          |            |                                                                                                                                                                                                                                                                                                    |
| <b>VRC01LS + 10-1074</b> (broadly neutralizing antibodies) in early-treated children | <a href="#">NCT03707977</a>                         | NIAID                    | Phase I/II | <a href="#">JAIDS. 2025 Mar 26. Sci Transl Med. 2023 15(703):eadh0004.</a><br>CROI 2023, Abstracts <a href="#">141</a> , <a href="#">828</a><br><a href="#">JAIDS. 91(2):182-8.</a><br>CROI 2022, <a href="#">Abstract 32</a><br>CROI 2021, <a href="#">Abstract 609</a> , <a href="#">Webcast</a> |
| <b>ABBV-382 (trosunilimab)</b> (anti- $\alpha_4\beta_7$ integrin antibody)           | <a href="#">NCT04554966</a>                         | AbbVie                   | Phase Ib   | CROI 2025, <a href="#">Abstract 709</a>                                                                                                                                                                                                                                                            |
| <b>10-1074</b> (broadly neutralizing monoclonal antibody)                            | <a href="#">NCT02511990</a>                         | Rockefeller University   | Phase I    | <a href="#">Nat Med. 2017 Feb;23(2):185-191</a>                                                                                                                                                                                                                                                    |
| <b>10-1074-LS + 3BNC117-LS</b> (long-acting broadly neutralizing antibodies)         | <a href="#">NCT03554408</a>                         | Rockefeller University   | Phase I    | N/A                                                                                                                                                                                                                                                                                                |
| <b>3BNC117</b>                                                                       | <a href="#">NCT02018510</a>                         | Rockefeller University   | Phase I    | <a href="#">Nature. 2015 Jun 25;522(7557):487-91</a>                                                                                                                                                                                                                                               |
| <b>3BNC117 + 10-1074</b>                                                             | <a href="#">NCT03571204</a>                         | NIAID                    | Phase I    | <a href="#">Nature. 2022 Jun; 606(7913):375-381.</a>                                                                                                                                                                                                                                               |
| <b>3BNC117 + 10-1074</b>                                                             | <a href="#">NCT02825797</a>                         | Rockefeller University   | Phase I    | <a href="#">Nat Med. 2020 Feb;26(2):222-227</a><br><a href="#">Nature. 2018 Sep;561:479-484.</a><br><a href="#">Nat Med. 2018 Sep 26.</a>                                                                                                                                                          |
| <b>3BNC117 + 10-1074</b>                                                             | <a href="#">NCT03526848</a>                         | Rockefeller University   | Phase I    | <a href="#">Nature. 2022 Apr 13</a><br>CROI 2022, <a href="#">Abstract 361</a>                                                                                                                                                                                                                     |
| <b>3BNC117-LS + 10-1074-LS</b> in viremic HIV+ individuals                           | <a href="#">NCT04250636</a>                         | Rockefeller University   | Phase I    | CROI 2022, <a href="#">Abstract 140</a>                                                                                                                                                                                                                                                            |
| <b>3BNC117-LS</b>                                                                    | <a href="#">NCT03254277</a>                         | Rockefeller University   | Phase I    | N/A                                                                                                                                                                                                                                                                                                |
| <b>elipovimab</b> (formerly GS-9722; PGT121-derived broadly neutralizing antibody)   | GS-US-420-3902<br><a href="#">Adisinsight entry</a> | Gilead Sciences          | Phase I    | CROI 2022, <a href="#">Abstract 349</a><br>CROI 2020, <a href="#">Abstract 39</a> , <a href="#">Webcast</a>                                                                                                                                                                                        |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                        | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)              | Phase   | Published/Presented Data                                                                                                                                                                                                    |
|------------------------------------------------------------------------------|------------------------------|---------------------------------------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>ANTIBODIES (Cont.)</b>                                                    |                              |                                       |         |                                                                                                                                                                                                                             |
| <b>PGDM1400 +/- PGT121 +/- VRC07-523LS</b> (broadly neutralizing antibodies) | <a href="#">NCT03205917</a>  | International AIDS Vaccine Initiative | Phase I | <a href="#">Nat Med 2022 May 12</a><br>CROI 2022, <a href="#">Abstract 139</a>                                                                                                                                              |
| <b>PGT121</b>                                                                | <a href="#">NCT02960581</a>  | International AIDS Vaccine Initiative | Phase I | <a href="#">Nat Med. 2021 Oct 7.</a><br>CROI 2019, <a href="#">Abstract 145</a> , <a href="#">Webcast</a>                                                                                                                   |
| <b>SAR441236</b> (tri-specific broadly neutralizing antibody)                | <a href="#">NCT03705169</a>  | NIAID                                 | Phase I | CROI 2024, <a href="#">Abstract 118</a>                                                                                                                                                                                     |
| <b>vedolizumab</b>                                                           | <a href="#">NCT02788175</a>  | NIAID                                 | Phase I | <a href="#">Sci Transl Med. 11(509):eaax3447.</a><br>AIDS 2018, <a href="#">WESS0102</a>                                                                                                                                    |
| <b>VRC01 + 10-1074</b>                                                       | <a href="#">NCT03831945</a>  | NIAID                                 | Phase I | Terminated: unable to recruit due to COVID                                                                                                                                                                                  |
| <b>VRC01</b> in acute HIV infection                                          | <a href="#">NCT02591420</a>  | NIAID                                 | Phase I | CROI 2023, <a href="#">Abstract 430</a>                                                                                                                                                                                     |
| <b>VRC01</b>                                                                 | <a href="#">NCT02411539</a>  | NIAID                                 | Phase I | <a href="#">OFID. 5(10):ofy242.</a>                                                                                                                                                                                         |
| <b>VRC01</b>                                                                 | <a href="#">NCT02471326</a>  | NIAID                                 | Phase I | <a href="#">N Engl J Med. 375(21):2037-2050</a>                                                                                                                                                                             |
| <b>VRC01</b>                                                                 | <a href="#">NCT02463227</a>  | NIAID                                 | Phase I | CROI 2023, <a href="#">Abstract 390</a><br>HIV Persistence Workshop 2022, <a href="#">Abstract PP 4.10 (slides)</a><br><a href="#">N Engl J Med. 375(21):2037-2050</a><br>CROI 2016, Abstract 32LB, <a href="#">Webcast</a> |
| <b>VRC01</b>                                                                 | <a href="#">NCT01950325</a>  | NIAID                                 | Phase I | <a href="#">Sci Transl Med. 7(319):319ra206</a>                                                                                                                                                                             |
| <b>VRC01LS, VRC07-523LS</b> (long-acting broadly neutralizing antibodies)    | <a href="#">NCT02840474</a>  | NIAID                                 | Phase I | <a href="#">JCI Insight 10(4):e181496.</a><br>IAS 2019, <a href="#">Abstract WEEA0305LB (video, at 45:36)</a>                                                                                                               |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                            | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                | Phase    | Published/Presented Data                                                                                                  |
|----------------------------------------------------------------------------------|------------------------------|-----------------------------------------|----------|---------------------------------------------------------------------------------------------------------------------------|
| <b>ANTI-CMV THERAPY</b>                                                          |                              |                                         |          |                                                                                                                           |
| <b>Ietermovir</b> (Prevymis)                                                     | <a href="#">NCT04840199</a>  | NIAID                                   | Phase II | CROI 2025, <a href="#">Abstract 182</a> ; CROI 2024, <a href="#">Abstract 354</a>                                         |
| <b>ANTI-FIBROTIC</b>                                                             |                              |                                         |          |                                                                                                                           |
| <b>ACE inhibitors</b>                                                            | <a href="#">NCT01535235</a>  | UCSF/amfAR                              | Phase IV | <a href="#">Pathog Immun. 2017;2(3):310-34.</a>                                                                           |
| <b>losartan</b>                                                                  | <a href="#">NCT01852942</a>  | University of Minnesota                 | Phase II | CROI 2020, <a href="#">Abstract 277</a>                                                                                   |
| <b>telmisartan</b>                                                               | <a href="#">NCT01928927</a>  | AIDS Clinical Trials Group              | Phase II | CROI 2019, <a href="#">Abstract 395</a><br><a href="#">J Infect Dis. 2018 217(11):1770-1781</a>                           |
| <b>telmisartan</b>                                                               | <a href="#">NCT02170246</a>  | Yale University                         | Phase I  | CROI 2019, <a href="#">Abstract 300</a>                                                                                   |
| <b>ANTI-INFLAMMATORY</b>                                                         |                              |                                         |          |                                                                                                                           |
| <b>canakinumab</b> (IL-1 $\beta$ inhibitor)                                      | <a href="#">NCT02272946</a>  | University of California, San Francisco | Phase II | <a href="#">J Am Coll Cardiol. 72(22):2809-2811.</a><br>CROI 2017, <a href="#">Abstract 126</a> , <a href="#">Webcast</a> |
| <b>CD24Fc</b> (human CD24 extracellular domain and human IgG1 Fc fusion protein) | <a href="#">NCT03960541</a>  | Oncolmmune, Inc.                        | Phase II | "Terminated (Business Reasons)"                                                                                           |
| High dose <b>vitamin D</b> supplementation                                       | <a href="#">NCT03426592</a>  | University of Melbourne                 | Phase II | <a href="#">JVE. 9(3):100345.</a><br>CROI 2022, <a href="#">Abstract 355</a>                                              |
| <b>Camu Camu</b> ( <i>Myrciaria dubia</i> )                                      | <a href="#">NCT04058392</a>  | McGill University Health Centre         | Phase I  | N/A                                                                                                                       |
| <b>CC-11050</b> (phosphodiesterase-4 inhibitor)                                  | <a href="#">NCT02652546</a>  | NIAID                                   | Phase I  | <a href="#">OFID. 6(6):ofz246.</a><br>AIDS 2018, <a href="#">Poster abstract LBPEB021</a>                                 |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                      | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                               | Phase      | Published/Presented Data                                                                                                                                                                  |
|--------------------------------------------------------------------------------------------|------------------------------|--------------------------------------------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>ANTI-PROLIFERATIVE</b>                                                                  |                              |                                                        |            |                                                                                                                                                                                           |
| <b>mycophenolate mofetil (MMF)</b>                                                         | <a href="#">NCT03262441</a>  | Fred Hutchinson Cancer Research Ctr                    | Phase I    | <a href="#">OFID 2022, ofac620</a><br>CROI 2020, <a href="#">Abstract 340</a>                                                                                                             |
| <b>ANTIRETROVIRAL THERAPY</b>                                                              |                              |                                                        |            |                                                                                                                                                                                           |
| <b>dolutegravir</b> in reservoirs                                                          | <a href="#">NCT02924389</a>  | Emory University                                       | Phase IV   | <a href="#">AIDS. 2018 Sep 24;32(15):2151-2159.</a>                                                                                                                                       |
| HIV reservoir dynamics after switching to dolutegravir in patients on a PI/r based regimen | <a href="#">NCT02513147</a>  | Hospital Universitari Vall d'Hebron Research Institute | Phase IV   | N/A                                                                                                                                                                                       |
| <b>raltegravir or efavirenz + tenofovir + emtricitabine</b>                                | <a href="#">NCT00734344</a>  | University of Alabama at Birmingham                    | Phase IV   | N/A                                                                                                                                                                                       |
| doravirine concentrations and antiviral activity in cerebrospinal fluid                    | <a href="#">NCT04079452</a>  | Fundacio Lluita Contra la SIDA                         | Phase III  | <a href="#">Clin Infect Dis. 2021 Sep 21;ciab835.</a>                                                                                                                                     |
| <b>IDOLTIB</b> : Impact of dolutegravir + lamivudine simplification on HIV-1 reservoirs    | <a href="#">NCT04034862</a>  | University of Liege                                    | Phase III  | N/A                                                                                                                                                                                       |
| <b>ABX464</b>                                                                              | <a href="#">NCT02735863</a>  | Abivax S.A.                                            | Phase II   | <a href="#">J. Virus Eradication 2019;5:10–22</a>                                                                                                                                         |
| <b>ABX464</b>                                                                              | <a href="#">NCT02990325</a>  | Abivax S.A.                                            | Phase I/II | <a href="#">J Infect Dis. jiad251.</a><br><a href="#">CID. 2021:ciab733.</a><br>CROI 2020, <a href="#">Abstract 335</a><br>HIV Persistence Workshop 2019, <a href="#">Abstract OP 8.3</a> |
| <b>ANTIRETROVIRAL THERAPY IN HIV CONTROLLERS</b>                                           |                              |                                                        |            |                                                                                                                                                                                           |
| <b>emtricitabine + rilpivirine + tenofovir</b>                                             | <a href="#">NCT01777997</a>  | AIDS Clinical Trials Group/NIAID                       | Phase IV   | <a href="#">J Infect Dis. jiaa294</a><br><a href="#">CID. 2019 May 25.</a><br>CROI 2019, <a href="#">Poster abstract 508</a><br>CROI 2018, <a href="#">Poster abstract 229</a>            |
| <b>raltegravir + tenofovir + emtricitabine</b>                                             | <a href="#">NCT01025427</a>  | University of California, San Francisco                | Phase IV   | <a href="#">PLoS Pathog. 2013;9(10):e1003691</a>                                                                                                                                          |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

Table 3. Completed Studies (Cont.)

| Trial                                                                                          | Trial Registry Identifier(s)        | Manufacturer/ Sponsor(s)              | Phase      | Published/Presented Data                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>ASSEMBLY INHIBITORS</b>                                                                     |                                     |                                       |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| BIT225                                                                                         | <a href="#">ACTRN12617000025336</a> | Biotron Limited                       | Phase II   | <a href="#">J Infect Dis. 2021 Jun 4;223(11):1914-1922.</a><br>CROI 2020, <a href="#">Abstract 506</a><br><a href="#">HIV DART 2018</a>                                                                                                                                                                                                                                                                                                                                    |
| BIT225                                                                                         | <a href="#">ACTRN12612000696897</a> | Biotron Limited                       | Phase I    | <a href="#">JAC. 2016 Mar;71(3):731-8</a>                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>CANNABINOIDS</b>                                                                            |                                     |                                       |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>GALIG-CBD:</b> Effects of cannabidiol on the activation of autophagy and inflammation genes | <a href="#">NCT05306249</a>         | Centre Hospitalier Régional d'Orléans | Phase II   | CROI 2025, Abstracts <a href="#">455</a> , <a href="#">916</a><br><a href="#">OFID. 11(9):ofae492.</a>                                                                                                                                                                                                                                                                                                                                                                     |
| <b>TN-TC11M2, TN-C200M2</b> oral capsules                                                      | <a href="#">NCT03550352</a>         | McGill University Health Center       | Phase II   | <a href="#">J Pers Med.14(7):745.</a><br>IAS 2023, <a href="#">Abstract EPB0270</a><br><a href="#">Cells. 12(14):1811.</a><br><a href="#">Biomedicines. 10(12):3168.</a>                                                                                                                                                                                                                                                                                                   |
| <b>COMBINATIONS</b>                                                                            |                                     |                                       |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>maraviroc, dolutegravir, dendritic cell vaccine, auranofin, nicotinamide</b>                | <a href="#">NCT02961829</a>         | Federal University of São Paulo       | Not listed | CROI 2023, <a href="#">Abstract 383</a><br>CROI 2021, <a href="#">Abstract 313</a><br><a href="#">AIDS Res Ther. 2022 Jan 12;19(1):2.</a><br>AIDS 2020, <a href="#">Abstract OAXLB0105</a><br>HIV Persistence Workshop 2019, <a href="#">Abstract OP 8.6</a><br><a href="#">Int J Antimicrob Agents. pii: S0924-8579(19)30212-2.</a><br>CROI 2019, <a href="#">Poster abstract 399</a><br>AIDS 2018, Abstract WEPDB0105 ( <a href="#">slides</a> , <a href="#">video</a> ) |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                          | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                               | Phase      | Published/Presented Data                                                                                                                        |
|------------------------------------------------------------------------------------------------|------------------------------|------------------------------------------------------------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>COMBINATIONS (Cont.)</b>                                                                    |                              |                                                                        |            |                                                                                                                                                 |
| <b>Perturbing of HIV reservoir with immune stimulation:</b> Fluarix, Pneumovax vaccines        | <a href="#">NCT02707692</a>  | University of California, San Diego                                    | Not listed | <a href="#">AIDS. 2024 Mar 25.</a><br>CROI 2022, <a href="#">Abstract 358</a>                                                                   |
| <b>ART +/- cyclosporine A, GM-CSF, pegylated interferon-alpha2b, IL-2</b>                      | <a href="#">NCT00979706</a>  | Juan A. Arnaiz                                                         | Phase IV   | <a href="#">Lancet HIV. 10(1):e42-e51.</a><br>AIDS 2022, <a href="#">Abstract OAA0205</a>                                                       |
| <b>MVA.HTI + ChAdOx1.HTI therapeutic vaccines + vesatolimod</b> (TLR7 agonist)                 | <a href="#">NCT04364035</a>  | Aelix Therapeutics                                                     | Phase IIa  | <a href="#">Nat Com 16(1):2146</a><br>CROI 2023, <a href="#">Abstract 433</a><br>HIV Persistence Workshop 2022, <a href="#">Abstract PP 7.4</a> |
| <b>ROADMAP:</b> romidepsin + 3BNC117                                                           | <a href="#">NCT02850016</a>  | Rockefeller University                                                 | Phase IIa  | <a href="#">Lancet Microbe. 2022 Mar;3(3):e203-e214</a><br>CROI 2020, <a href="#">Abstract 38</a> , <a href="#">Webcast</a>                     |
| <b>TITAN:</b> lefitolimod + 3BNC117 + 10-1074 (TLR9 agonist + broadly neutralizing antibodies) | <a href="#">NCT03837756</a>  | University of Aarhus                                                   | Phase IIa  | <a href="#">Nat Med. 2023 Sep 11</a><br>CROI 2023, <a href="#">Abstract 136</a>                                                                 |
| <b>VRC07-523LS, CAP256V2LS, vesatolimod</b>                                                    | <a href="#">NCT05281510</a>  | Gilead Sciences                                                        | Phase IIa  | CROI 2025, <a href="#">Abstract 105</a><br><a href="#">IAS 2025, Abstracts EP1003, LB32</a>                                                     |
| Adoptive transfer of <b>haploidentical natural killer cells</b> and <b>IL-2</b>                | <a href="#">NCT03346499</a>  | University of Minnesota - Clinical and Translational Science Institute | Phase II   | <a href="#">J Infect Dis. 2024 Jan 11:jiad578</a>                                                                                               |
| <b>Albuvirtide</b> (fusion inhibitor) + <b>3BNC117</b>                                         | <a href="#">NCT04819347</a>  | Frontier Biotechnologies Inc.                                          | Phase II   | N/A, unknown if study opened                                                                                                                    |
| <b>ASC22</b> (anti-PD-L1 antibody) + <b>chidamide</b> (HDAC inhibitor)                         | <a href="#">NCT05129189</a>  | Shanghai Public Health Clinical Center                                 | Phase II   | <a href="#">STTT. 9(1):231.</a><br>IAS 2023, <a href="#">Abstract LBEPB18</a>                                                                   |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                                     | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                               | Phase    | Published/Presented Data                                                                                                                                                                                                                                                                                                        |
|---------------------------------------------------------------------------------------------------------------------------|------------------------------|--------------------------------------------------------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>COMBINATIONS (Cont.)</b>                                                                                               |                              |                                                        |          |                                                                                                                                                                                                                                                                                                                                 |
| <b>eCLEAR:</b> romidepsin + 3BNC117                                                                                       | <a href="#">NCT03041012</a>  | Aarhus University Hospital                             | Phase II | CROI 2024, <a href="#">Abstract 486</a><br>HIV Persistence 2022, <a href="#">Abstract OP 1.9 (slides)</a><br><a href="#">Nat Med. 2022 Oct 17</a><br>CROI 2022, <a href="#">Abstract 62</a> , <a href="#">Abstract 122</a>                                                                                                      |
| <b>ERAMUNE-01</b><br>(antiretroviral intensification +/- interleukin-7)                                                   | <a href="#">NCT01019551</a>  | ORVACS/Cytheris SA/Merck Sharp & Dohme Corp./Pfizer    | Phase II | <a href="#">AIDS. 2016 Jan;30(2):221-30</a>                                                                                                                                                                                                                                                                                     |
| <b>ERAMUNE-02</b><br>(DNA/Ad5 vaccine, ART intensification)                                                               | <a href="#">NCT00976404</a>  | Vical/GenVec/CHERUB/NIH Vaccine Research Center/ORVACS | Phase II | <a href="#">Lancet HIV. 2015 Mar;2(3):e82-91</a><br>CROI 2014, <a href="#">Poster abstract 422</a>                                                                                                                                                                                                                              |
| <b>MVA HIV-B +/- vedolizumab</b> (viral vector vaccine +/- anti- $\alpha_4\beta_7$ integrin antibody)                     | <a href="#">NCT04120415</a>  | ANRS                                                   | Phase II | Stopped due to logistical issues                                                                                                                                                                                                                                                                                                |
| <b>Research in Viral Eradication of HIV Reservoirs (RIVER):</b> ART, ChAdV63.HIVconsV & MVA.HIVconsV vaccines, vorinostat | <a href="#">NCT02336074</a>  | Imperial College London                                | Phase II | <a href="#">J Exp Med. 221(11):e20241091.</a><br>CROI 2024, <a href="#">Abstract 504</a><br><a href="#">Sci Rep. 13(1):17155.</a><br><a href="#">J Virus Erad. 2021 Sep 14; 7(3):100056.</a><br><a href="#">Lancet. 395 (10227):888-898</a><br>AIDS 2018, Abstract TUA0202LB ( <a href="#">slides</a> , <a href="#">video</a> ) |
| <b>UB-421 + chidamide</b>                                                                                                 | <a href="#">NCT05056974</a>  | United BioPharma                                       | Phase II | N/A                                                                                                                                                                                                                                                                                                                             |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                                               | Trial Registry Identifier(s)                                              | Manufacturer/ Sponsor(s)                               | Phase      | Published/Presented Data                                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>COMBINATIONS (Cont.)</b>                                                                                                         |                                                                           |                                                        |            |                                                                                                                                                                                              |
| <b>vorinostat +/- tamoxifen</b> in postmenopausal women                                                                             | <a href="#">NCT03382834</a>                                               | NIAID                                                  | Phase II   | <a href="#">Clin Infect Dis. 2022 Feb 17:ciac136.</a><br>CROI 2020, <a href="#">Abstract 333</a> , <a href="#">Webcast</a><br>HIV Persistence Workshop 2019, <a href="#">Abstract OP 3.2</a> |
| <b>disulfiram + vorinostat</b>                                                                                                      | <a href="#">NCT03198559</a><br>(suspended due to neurotoxicity)           | The Peter Doherty Institute for Infection and Immunity | Phase I/II | <a href="#">AIDS. 2021 Sep 29.</a><br>CROI 2019, <a href="#">Abstract 401</a>                                                                                                                |
| <b>GTU-MultiHIV B-clade + MVA HIV-B +/- vedolizumab</b> (DNA + viral vector vaccines +/- anti- $\alpha_4\beta_7$ integrin antibody) | <a href="#">NCT02972450</a>                                               | Inserm-ANRS                                            | Phase I/II | Terminated due to bankruptcy of FITBiotech                                                                                                                                                   |
| <b>panobinostat + pegylated interferon-alpha2a</b>                                                                                  | <a href="#">NCT02471430</a>                                               | Massachusetts General Hospital                         | Phase I/II | <a href="#">Cell. 187(5):1238-1254.e14.</a><br>CROI 2022, <a href="#">Abstract 357</a><br>CROI 2020, <a href="#">Abstract 341</a>                                                            |
| <b>Vacc-4x</b> (peptide-based therapeutic vaccine) + <b>romidepsin</b>                                                              | <a href="#">NCT02092116</a>                                               | Bionor Immuno AS/Celgene                               | Phase I/II | CROI 2023, <a href="#">Abstract 337</a><br>CROI 2019, <a href="#">Abstract 397</a><br><a href="#">Lancet HIV. 2016 Oct;3(10):e463-72</a>                                                     |
| <b>Vacc-4x + lenalidomide</b>                                                                                                       | <a href="#">NCT01704781</a>                                               | Bionor Immuno AS                                       | Phase I/II | <a href="#">Results posted in clinicaltrials.gov</a>                                                                                                                                         |
| <b>vorinostat + hydroxychloroquine + maraviroc (VHM)</b>                                                                            | <a href="#">NCT02475915</a><br><a href="#">NCT02470351</a> (CNS substudy) | South East Asia Research Collaboration with Hawaii     | Phase I/II | <a href="#">Clin Infect Dis. 73(7):e1885-e1892.</a><br><a href="#">J Virus Erad. 2020 (6) 100004</a><br>AIDS 2016, <a href="#">Abstract TUAX0101LB</a>                                       |
| <b>elipovimab</b> (formerly GS-9722) +/- <b>vesatolimod</b>                                                                         | <a href="#">GS-US-420-3902</a> (#18 on list, no clinicaltrials.gov entry) | Gilead Sciences                                        | Phase Ib   | N/A, elipovimab discontinued (see <a href="#">Adis Insight</a> )                                                                                                                             |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                    | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                                           | Phase   | Published/Presented Data                                                                                                                                                                                                                                                     |
|----------------------------------------------------------------------------------------------------------|------------------------------|------------------------------------------------------------------------------------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>COMBINATIONS (Cont.)</b>                                                                              |                              |                                                                                    |         |                                                                                                                                                                                                                                                                              |
| Adoptive transfer of <b>haploidentical NK cells</b> and <b>N-803</b>                                     | <a href="#">NCT03899480</a>  | University of Minnesota - Clinical and Translational Science Institute             | Phase I | <a href="#">J Infect Dis. 2024 Jan 11:jiad578</a>                                                                                                                                                                                                                            |
| <b>AGS-004 + vorinostat</b>                                                                              | <a href="#">NCT02707900</a>  | NIAID                                                                              | Phase I | <a href="#">Sci Rep. 10(1):5134. IAS 2019, Poster abstract MOPEB272</a>                                                                                                                                                                                                      |
| <b>CD4-ZETA</b> gene-modified T cells +/- interleukin-2 (IL-2)                                           | <a href="#">NCT01013415</a>  | University of Pennsylvania                                                         | Phase I | CROI 2020, <a href="#">Abstract 337</a> , <a href="#">Webcast Mol Ther. 5(6):788-97</a>                                                                                                                                                                                      |
| <b>chemotherapy + maraviroc</b> in people with non-Hodgkin lymphoma                                      | <a href="#">NCT02486510</a>  | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Phase I | Terminated due to futility criteria                                                                                                                                                                                                                                          |
| <b>Chidamide + CAR-T or TCR-T cell therapy</b>                                                           | <a href="#">NCT03980691</a>  | Guangzhou 8th People's Hospital                                                    | Phase I | <a href="#">Cell Discov. 10(1):49.</a>                                                                                                                                                                                                                                       |
| <b>DCV3</b> (dendritic cell-based vaccine pulsed with autologous inactivated HIV) + pegylated interferon | <a href="#">NCT02767193</a>  | Judit Pich Martínez, Fundació Clínic per la Recerca Biomèdica                      | Phase I | <a href="#">Front Immunol. 2021 Nov 11;12:767370. CROI 2020, Abstract 282</a><br><a href="#">J Infect Dis. 2020; 221(10):1740-1742.</a>                                                                                                                                      |
| <b>MVA-B</b> (viral vector vaccine) +/- <b>disulfiram</b>                                                | <a href="#">NCT01571466</a>  | Hospital Clinic of Barcelona/HIVACAT                                               | Phase I | <a href="#">PLoS One. 2015 Nov 6;10(11):e0141456. JAC. pii: dkv046.</a>                                                                                                                                                                                                      |
| <b>MVA.HIVconsv + romidepsin</b>                                                                         | <a href="#">NCT02616874</a>  | IrsiCaixa                                                                          | Phase I | <a href="#">EBioMedicine. 95:104732. CROI 2023, Abstracts 385, 481</a><br><a href="#">Microbiome. 10(1):59. EBioMedicine. 78:103956. AIDS. 2021 Nov 3 JAC. dkaa523. Front Immunol. 11:823. CROI 2019, Abstract 438</a><br><a href="#">CROI 2017, Abstract 119LB, Webcast</a> |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                    | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                               | Phase    | Published/Presented Data                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------------------------------------------------------------------------|------------------------------|------------------------------------------------------------------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>COMBINATIONS (Cont.)</b>                                              |                              |                                                                        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>peginterferon alfa-2b + 3BNC117 + 10-1074 (BEAT-2)</b>                | <a href="#">NCT03588715</a>  | Wistar Institute                                                       | Phase I  | CROI 2025, <a href="#">Abstract 149</a><br>CROI 2024, Abstracts <a href="#">179</a> , <a href="#">511</a> , <a href="#">1091</a> , <a href="#">1106</a><br><a href="#">HIV Res Clin Pract. 24(1):2267825.</a><br>CROI 2023, Abstracts <a href="#">319</a> , <a href="#">326</a> , <a href="#">384</a> , <a href="#">431</a><br>HIV Persistence Workshop 2022, <a href="#">Abstracts PP 7.2, 8.10</a><br>CROI 2022, <a href="#">Abstract 352</a> |
| <b>vorinostat + HXTC: HIV 1 antigen expanded specific T cell therapy</b> | <a href="#">NCT03212989</a>  | Julia Sung, MD, University of North Carolina, Chapel Hill              | Phase I  | <a href="#">J Infect Dis. jiad423.</a><br>IAS 2023, <a href="#">Abstract TUPEA02</a>                                                                                                                                                                                                                                                                                                                                                            |
| <b>VRC07-523LS + vorinostat</b>                                          | <a href="#">NCT03803605</a>  | University of North Carolina, Chapel Hill                              | Phase I  | <a href="#">J Infect Dis. jiab487.</a><br>IAS 2021, <a href="#">Abstract OALA01LB03 (video)</a>                                                                                                                                                                                                                                                                                                                                                 |
| <b>CYTOKINES</b>                                                         |                              |                                                                        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>interleukin-2 (IL-2)</b>                                              | <a href="#">NCT03308786</a>  | Case Western Reserve University                                        | Phase II | HIV Persistence Workshop 2022, <a href="#">Abstract OP 8.2 (slides)</a>                                                                                                                                                                                                                                                                                                                                                                         |
| Effect of <b>N-803</b> on B cell follicles                               | <a href="#">NCT04808908</a>  | University of Minnesota                                                | Phase I  | <a href="#">JCI Insight. e190831.</a>                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>N-803</b>                                                             | <a href="#">NCT02191098</a>  | University of Minnesota - Clinical and Translational Science Institute | Phase I  | <a href="#">Nat Med. 2022 Jan 31.</a><br>CROI 2018, <a href="#">Poster abstract 356</a>                                                                                                                                                                                                                                                                                                                                                         |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                               | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)        | Phase       | Published/Presented Data                                                                                                                                                                                                                                 |
|-----------------------------------------------------------------------------------------------------|------------------------------|---------------------------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>DUAL-AFFINITY RE-TARGETING (DART) MOLECULES</b>                                                  |                              |                                 |             |                                                                                                                                                                                                                                                          |
| <b>MGD020 +/- MGD014</b>                                                                            | <a href="#">NCT05261191</a>  | MacroGenics                     | Phase I     | N/A                                                                                                                                                                                                                                                      |
| <b>MGD014</b>                                                                                       | <a href="#">NCT03570918</a>  | MacroGenics                     | Phase I     | AIDS 2022, <a href="#">Abstract OAA0403</a><br>Results posted in <a href="#">clinicaltrials.gov</a>                                                                                                                                                      |
| <b>GENE THERAPIES</b>                                                                               |                              |                                 |             |                                                                                                                                                                                                                                                          |
| <b>OZ1</b>                                                                                          | <a href="#">NCT00074997</a>  | Janssen-Cilag Pty Ltd           | Phase II    | <a href="#">Nat Med. 2009 Mar; 15(3): 285–292.</a>                                                                                                                                                                                                       |
| <b>EBT-101</b> (CRISPR/Cas9 targeting HIV provirus)                                                 | <a href="#">NCT05144386</a>  | Excision BioTherapeutics        | Phase I/IIa | <a href="#">AIDS 2024 SY26</a><br>ESGCT Congress 2023, <a href="#">Abstract OR31</a>                                                                                                                                                                     |
| <b>Cal-1</b> : Dual anti-HIV gene transfer construct                                                | <a href="#">NCT01734850</a>  | Calimmune                       | Phase I/II  | <a href="#">Results posted in clinicaltrials.gov</a>                                                                                                                                                                                                     |
| <b>SB-728mR-T</b> (autologous CD4 T cells genetically modified at the CCR5 gene) + cyclophosphamide | <a href="#">NCT02225665</a>  | Sangamo BioSciences             | Phase I/II  | N/A                                                                                                                                                                                                                                                      |
| <b>SB-728-T</b> + cyclophosphamide                                                                  | <a href="#">NCT01543152</a>  | Sangamo BioSciences             | Phase I/II  | CROI 2023, <a href="#">Abstract 182</a><br><a href="#">bioRxiv 2021.02.28</a><br>CROI 2016, <a href="#">Poster abstract 358LB</a><br>CROI 2015, <a href="#">Poster abstract 434</a><br>CROI 2014, <a href="#">Abstract 141</a> , <a href="#">Webcast</a> |
| <b>SB-728-T</b>                                                                                     | <a href="#">NCT01252641</a>  | Sangamo BioSciences             | Phase I/II  | N/A                                                                                                                                                                                                                                                      |
| <b>SB-728-T</b>                                                                                     | <a href="#">NCT03666871</a>  | Case Western Reserve University | Phase I/II  | CROI 2025, <a href="#">Abstract 536</a>                                                                                                                                                                                                                  |

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                         | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                                          | Phase      | Published/Presented Data                                                                                                                  |
|-----------------------------------------------------------------------------------------------|------------------------------|-----------------------------------------------------------------------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| <b>GENE THERAPIES (Cont.)</b>                                                                 |                              |                                                                                   |            |                                                                                                                                           |
| <b>VRX496</b> (gene-modified autologous CD4 T cells)                                          | <a href="#">NCT00295477</a>  | University of Pennsylvania                                                        | Phase I/II | <a href="#">Blood. 2013 Feb 28; 121(9): 1524–1533</a>                                                                                     |
| <b>AGT103-T</b> (gene-modified HIV-specific CD4 T cells)                                      | <a href="#">NCT04561258</a>  | American Gene Technologies International Inc.                                     | Phase I    | <a href="#">Front Med 2022 9:1044713.</a>                                                                                                 |
| <b>C34-CXCR4</b> (autologous CD4 T cells gene-modified to express HIV-inhibiting C34 peptide) | <a href="#">NCT03020524</a>  | University of Pennsylvania                                                        | Phase I    | N/A                                                                                                                                       |
| <b>HGTV43</b>                                                                                 | No clinicaltrials.gov entry  | Enzo Biochem                                                                      | Phase I    | AIDS 2006, <a href="#">Abstract MOPDA06</a>                                                                                               |
| Long-term follow-up of HIV+ participants exposed to <b>SB-728-T</b> or <b>SB-728mR-T</b>      | <a href="#">NCT04201782</a>  | Sangamo Therapeutics                                                              | Phase I    | <a href="#">No significant safety issues</a>                                                                                              |
| <b>MazF-T</b> (redirected MazF-CD4 autologous T cells)                                        | <a href="#">NCT01787994</a>  | Takara Bio/University of Pennsylvania                                             | Phase I    | <a href="#">Mol Ther 2020 Nov 10 CROI 2015, Poster abstract 402</a>                                                                       |
| Redirected high affinity Gag-specific T cells                                                 | <a href="#">NCT00991224</a>  | University of Pennsylvania/Adaptimmune                                            | Phase I    | Study closed (safety): <a href="#">Mol Ther. 2015 Jul; 23(7): 1149–1159.</a>                                                              |
| <b>SB-728mR-T</b> + cyclophosphamide                                                          | <a href="#">NCT02388594</a>  | University of Pennsylvania                                                        | Phase I    | <a href="#">J Clin Invest. 2021. CROI 2019, Abstract 25, Webcast</a>                                                                      |
| <b>SB-728-T</b>                                                                               | <a href="#">NCT01044654</a>  | Sangamo BioSciences                                                               | Phase I    | CROI 2023, <a href="#">Abstract 182</a><br><a href="#">bioRxiv 2021.02.28</a><br>ICAAC 2014, Abstract H-643; ICAAC 2013, Abstract H-1464c |
| <b>SB-728-T</b>                                                                               | <a href="#">NCT00842634</a>  | Sangamo Biosciences/University of Pennsylvania                                    | Phase I    | <a href="#">N Engl J Med. 2014 Mar 6;370(10):901–10</a>                                                                                   |
| shRNA-modified CD34+ cells                                                                    | <a href="#">NCT03517631</a>  | Shanghai Public Health Clinical Center                                            | Phase I    | N/A                                                                                                                                       |
| <b>TCTIWHI</b> : Third-generation CAR-T-cell therapy                                          | <a href="#">NCT04863066</a>  | Beijing 302 Hospital                                                              | Phase I    | N/A                                                                                                                                       |
| <b>GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS</b>                                    |                              |                                                                                   |            |                                                                                                                                           |
| CRISPR CCR5 modified CD34+ cells                                                              | <a href="#">NCT03164135</a>  | 307 Hospital of PLA (Affiliated Hospital of Academy to Military Medical Sciences) | Not listed | <a href="#">N Engl J Med. 2019 Sep 11</a>                                                                                                 |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                             | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                | Phase      | Published/Presented Data                                                                                                                                                                                            |
|---------------------------------------------------------------------------------------------------|------------------------------|-----------------------------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS (Cont.)</b>                                |                              |                                         |            |                                                                                                                                                                                                                     |
| Stem cells gene-modified with M87o vector encoding HIV-inhibiting C46 peptide                     | <a href="#">NCT00858793</a>  | Universitätsklinikum Hamburg-Eppendorf  | Phase I/II | N/A                                                                                                                                                                                                                 |
| Stem cells gene-modified with <b>Cal-1</b>                                                        | <a href="#">NCT03593187</a>  | Assistance Publique - Hôpitaux de Paris | Phase I/II | <a href="#">Mol Ther Methods Clin Dev. 2019;13:303-309</a>                                                                                                                                                          |
| Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ)                  | <a href="#">NCT00569985</a>  | City of Hope Medical Center             | Phase I    | <a href="#">Sci Transl Med. 2010 Jun 16; 2(36): 36ra43.</a>                                                                                                                                                         |
| <b>GONADOTROPIN-RELEASING HORMONE (GnRH) AGONISTS</b>                                             |                              |                                         |            |                                                                                                                                                                                                                     |
| triptorelin acetate depot                                                                         | <a href="#">NCT03536234</a>  | Immune System Regulation AB             | Phase II   | N/A                                                                                                                                                                                                                 |
| <b>HORMONES</b>                                                                                   |                              |                                         |            |                                                                                                                                                                                                                     |
| <b>somatotropin</b> (human growth hormone)                                                        | <a href="#">NCT03091374</a>  | McGill University Health Center         | Phase II   | CROI 2021, <a href="#">Abstract 298</a> , <a href="#">Webcast</a>                                                                                                                                                   |
| <b>IMAGING STUDIES</b>                                                                            |                              |                                         |            |                                                                                                                                                                                                                     |
| 123I radiolabeled 3BNC117                                                                         | <a href="#">NCT03468582</a>  | University of Lausanne Hospitals        | Phase I    | N/A                                                                                                                                                                                                                 |
| Radiolabeled 3BNC117 + Copper-64 radio isotope followed by MRI/PET scanning to detect HIV in vivo | <a href="#">NCT03063788</a>  | Bayside Health                          | Phase I    | <a href="#">EBioMedicine. 2021 Feb 25;65:103252.</a><br>AIDS 2020, <a href="#">Abstract PEA0060</a>                                                                                                                 |
| <b>IMMUNE CHECKPOINT INHIBITORS</b>                                                               |                              |                                         |            |                                                                                                                                                                                                                     |
| <b>ASC22</b> (anti-PD-L1 antibody)                                                                | <a href="#">NCT05330143</a>  | Ascleptis Pharmaceuticals Co., Ltd.     | Phase II   | N/A                                                                                                                                                                                                                 |
| <b>durvalumab</b> (anti-PD-L1 antibody) in solid tumors                                           | <a href="#">NCT03094286</a>  | Spanish Lung Cancer Group               | Phase II   | ESMO 2020, <a href="#">Abstract 1275P</a><br><a href="#">JAMA Oncol. 2020 Jul 1;6(7):1063-1067</a>                                                                                                                  |
| <b>cemiplimab</b> (anti-PD-1 antibody)                                                            | <a href="#">NCT03787095</a>  | NIAID                                   | Phase I/II | <a href="#">OFID 11(3):ofad694.</a><br><a href="#">JAIDS. 87(5):e234-e236.</a><br>2020 Community HIV Cure Research Workshop ( <a href="#">slides</a> , <a href="#">video</a> )<br><a href="#">ACTG announcement</a> |
| <b>budigalimab</b> (anti-PD-1 antibody)                                                           | <a href="#">NCT04223804</a>  | AbbVie                                  | Phase Ib   | CROI 2024, <a href="#">Abstract 106</a><br>EACS 2023, <a href="#">Abstract PS10.Q3</a>                                                                                                                              |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                                                           | Trial Registry Identifier(s)                                                       | Manufacturer/ Sponsor(s)                                        | Phase   | Published/Presented Data                                                                                                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>IMMUNE CHECKPOINT INHIBITORS (Cont.)</b>                                                                                                     |                                                                                    |                                                                 |         |                                                                                                                                                                                                                                        |
| <b>BMS-936559</b> (anti-PD-L1 antibody)                                                                                                         | <a href="#">NCT02028403</a>                                                        | National Institute of Allergy and Infectious Diseases (NIAID)   | Phase I | <a href="#">J Infect Dis. 2017 Jun 1;215(11):1725-1733</a><br>CROI 2016, <a href="#">Abstract 25, Webcast</a>                                                                                                                          |
| <b>budigalimab</b> (anti-PD-1 antibody)                                                                                                         | <a href="#">NCT04799353</a>                                                        | AbbVie                                                          | Phase I | EACS 2023, <a href="#">Abstract PS10.O3</a>                                                                                                                                                                                            |
| <b>ipilimumab</b> (anti-CTLA-4 antibody)                                                                                                        | <a href="#">NCT03407105</a>                                                        | Medarex                                                         | Phase I | <a href="#">PLoS One. 2018 Jun 7;13(6):e0198158</a>                                                                                                                                                                                    |
| <b>nivolumab</b> (anti-PD-1 antibody) + <b>ipilimumab</b> (anti-CTLA-4 antibody) in treating patients with advanced HIV associated solid tumors | <a href="#">NCT02408861</a><br>(listed as terminated due to inadequate enrollment) | National Cancer Institute (NCI)                                 | Phase I | AIDS 2024, <a href="#">Abstract OAA1308</a><br>Cancer. 2023 Nov 14. <a href="#">Clin Infect Dis. 2021 ciaa1530</a><br>HIV Persistence Workshop 2019, <a href="#">Abstract OP 5.5</a><br><a href="#">J. Clin Oncol 36, no. 15 suppl</a> |
| <b>pembrolizumab</b> (anti-PD-1 antibody) in treating patients with HIV and relapsed, refractory, or disseminated malignant neoplasms           | <a href="#">NCT02595866</a>                                                        | National Cancer Institute (NCI)                                 | Phase I | CROI 2023, <a href="#">Abstract 181</a><br><a href="#">Sci Transl Med. 14(629):eabl3836</a><br><a href="#">JAMA Oncol. Sep 1;5(9):1332-1339</a><br>CROI 2019, <a href="#">Abstract 27</a><br>CROI 2018, <a href="#">Abstract 656LB</a> |
| <b>pembrolizumab</b> (anti-PD-1 antibody) single dose                                                                                           | <a href="#">NCT03239899</a>                                                        | National Institute of Neurological Disorders and Stroke (NINDS) | Phase I | HIV Persistence Workshop 2022, <a href="#">Abstract OP 1.10 (slides)</a>                                                                                                                                                               |
| <b>IRON CHELATORS</b>                                                                                                                           |                                                                                    |                                                                 |         |                                                                                                                                                                                                                                        |
| <b>deferiprone</b>                                                                                                                              | <a href="#">NCT02456558</a>                                                        | ApoPharma                                                       | Phase I | N/A                                                                                                                                                                                                                                    |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                    | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                                                                   | Phase         | Published/Presented Data                                                                                                                                                                                           |
|----------------------------------------------------------|------------------------------|------------------------------------------------------------------------------------------------------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>JANUS KINASE INHIBITORS</b>                           |                              |                                                                                                            |               |                                                                                                                                                                                                                    |
| <b>ruxolitinib</b>                                       | <a href="#">NCT02475655</a>  | NIAID                                                                                                      | Phase II      | CROI 2024, <a href="#">Abstract 521</a><br>IAS 2023, <a href="#">Abstract TUPEB15</a><br><a href="#">JCP. 61(12):1555-1566.</a><br><a href="#">Clin Infect Dis. 2021</a><br>CROI 2019, <a href="#">Abstract 37</a> |
| <b>LATENCY-REVERSING AGENTS</b>                          |                              |                                                                                                            |               |                                                                                                                                                                                                                    |
| <b>disulfiram</b> (acetaldehyde dehydrogenase inhibitor) | <a href="#">NCT01286259</a>  | University of California, San Francisco/<br>Johns Hopkins University/amfAR                                 | Not specified | <a href="#">Clin Infect Dis. 2014 58 (6): 883–90</a>                                                                                                                                                               |
| <b>Chidamide</b>                                         | <a href="#">NCT02902185</a>  | Tang-Du Hospital                                                                                           | Phase II/III  | N/A                                                                                                                                                                                                                |
| <b>vorinostat</b> (HDAC inhibitor)                       | <a href="#">NCT01365065</a>  | Bayside Health/Merck                                                                                       | Phase II      | <a href="#">PLoS Pathog. 2014;10(10):e1004473</a>                                                                                                                                                                  |
| <b>valproic acid</b> (HDAC inhibitor)                    | <a href="#">NCT00289952</a>  | McGill University                                                                                          | Phase II      | <a href="#">HIV Med. 2012 May;13(5):291–6</a>                                                                                                                                                                      |
| <b>valproic acid</b>                                     | <a href="#">NCT00614458</a>  | University of North Carolina at Chapel Hill/NIAID/Abbott/Merck Sharp & Dohme                               | Phase II      | <a href="#">PLoS One. 2010 5(2): e9390</a>                                                                                                                                                                         |
| <b>Chidamide</b> (HDAC inhibitor)                        | <a href="#">NCT02513901</a>  | Tang-Du Hospital                                                                                           | Phase I/II    | <a href="#">HIV Med. 2020 Dec;21(11):747-757.</a><br>AIDS 2018, Abstract WEAA0101 ( <a href="#">slides</a> , <a href="#">video</a> )                                                                               |
| <b>disulfiram</b>                                        | <a href="#">NCT01944371</a>  | University of California, San Francisco/Monash University/amfAR                                            | Phase I/II    | CROI 2015, <a href="#">Poster abstract 428LB</a>                                                                                                                                                                   |
| <b>panobinostat</b> (HDAC inhibitor)                     | <a href="#">NCT01680094</a>  | University of Aarhus/Massachusetts General Hospital/Monash University/Karolinska Institutet/Novartis/amfAR | Phase I/II    | CROI 2015, <a href="#">Abstract 109</a> , <a href="#">Webcast The Lancet HIV. 2014 Oct; 1(1): e13–e21</a>                                                                                                          |
| <b>romidepsin</b> (HDAC inhibitor)                       | <a href="#">NCT01933594</a>  | AIDS Clinical Trials Group/NIAID/Gilead                                                                    | Phase I/II    | <a href="#">JID, jiaa777</a><br>CROI 2019, <a href="#">Abstract 26</a> , <a href="#">Webcast</a><br>CROI 2018, <a href="#">Abstract 72</a> , <a href="#">Webcast</a>                                               |
| <b>valproic acid + pyrimethamine</b>                     | <a href="#">NCT03525730</a>  | Erasmus Medical Center                                                                                     | Phase I/II    | <a href="#">Sci Adv. 2023 Mar 17;9(11):eade6675.</a>                                                                                                                                                               |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                             | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                                           | Phase        | Published/Presented Data                                                                                                                                                                                                                                                                   |
|-----------------------------------------------------------------------------------|------------------------------|------------------------------------------------------------------------------------|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>LATENCY-REVERSING AGENTS (Cont.)</b>                                           |                              |                                                                                    |              |                                                                                                                                                                                                                                                                                            |
| <b>vorinostat</b>                                                                 | <a href="#">NCT01319383</a>  | University of North Carolina at Chapel Hill/NIAID/Merck.                           | Phase I/II   | <a href="#">J Clin Invest. 2017 Aug 1;127(8):3126-3135.</a><br><a href="#">J Infect Dis. 2014 Sep 1;210(5):728-35</a><br><a href="#">Nature. 487(7408):482-5</a>                                                                                                                           |
| <b>bryostatatin 1</b> (PKC agonist)                                               | <a href="#">NCT02269605</a>  | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Phase I      | <a href="#">AIDS. 2016 Jun 1;30(9):1385-92.</a>                                                                                                                                                                                                                                            |
| <b>Euphorbia kansui</b>                                                           | <a href="#">NCT04503928</a>  | Shanghai Public Health Clinical Center                                             | Phase I      | <a href="#">IAS 2025, Abstract EP0059</a>                                                                                                                                                                                                                                                  |
| <b>Kansui</b> (traditional Chinese medicine with ingenols)                        | <a href="#">NCT02531295</a>  | UCSF                                                                               | Phase I      | Study terminated                                                                                                                                                                                                                                                                           |
| <b>mTOR INHIBITORS</b>                                                            |                              |                                                                                    |              |                                                                                                                                                                                                                                                                                            |
| Impact of <b>Everolimus</b> on HIV persistence post kidney or liver transplant    | <a href="#">NCT02429869</a>  | UCSF                                                                               | Phase IV     | <a href="#">Am J Transplant. 21(5):1765-1779.</a>                                                                                                                                                                                                                                          |
| <b>metformin</b>                                                                  | <a href="#">NCT04500678</a>  | University of Hawaii                                                               | Phase II/III | <a href="#">ARHR 36(4):303-305.</a><br><a href="#">ARHR. 37(1):24-33.</a><br><a href="#">Aging Cell 23(1):e13926.</a>                                                                                                                                                                      |
| <b>Sirolimus</b>                                                                  | <a href="#">NCT02440789</a>  | ACTG                                                                               | Phase I/II   | <a href="#">Cell Rep Med. 101745.</a><br>CROI 2019, <a href="#">Abstract 131</a> , <a href="#">Webcast</a>                                                                                                                                                                                 |
| <b>metformin</b>                                                                  | <a href="#">NCT02659306</a>  | McGill University Health Center                                                    | Phase I      | <a href="#">EBioMedicine 65:103270</a><br>CROI 2020, <a href="#">Poster abstract 229</a><br>CROI 2019, <a href="#">Poster abstract 301</a>                                                                                                                                                 |
| <b>OBSERVATIONAL STUDIES</b>                                                      |                              |                                                                                    |              |                                                                                                                                                                                                                                                                                            |
| <b>2000HIV</b> : 2000 HIV human functional genomics partnership program           | <a href="#">NCT03994835</a>  | Radboud University                                                                 | N/A          | CROI 2025, Abstracts <a href="#">355</a> , <a href="#">462</a> , <a href="#">470</a> , <a href="#">487</a> , <a href="#">499</a> , <a href="#">565</a><br>CROI 2024, Abstracts <a href="#">319</a> , <a href="#">442</a> , <a href="#">515</a><br><a href="#">Front Immunol. 13:982746</a> |
| <b>2000HIVTrained</b> : 2000 HIV trained innate immunity in HIV elite controllers | <a href="#">NCT04968717</a>  | Radboud University                                                                 | N/A          | CROI 2025, Abstract <a href="#">499</a><br>CROI 2024, <a href="#">Abstract 442</a><br>CROI 2023, Abstracts <a href="#">313</a> , <a href="#">314</a>                                                                                                                                       |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                                                                    | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)   | Phase | Published/Presented Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>OBSERVATIONAL STUDIES (Cont.)</b>                                                                                                                     |                              |                            |       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>ACTG A5321:</b> Decay of HIV-1 reservoirs in subjects on long-term antiretroviral therapy: The ACTG HIV reservoirs cohort (AHRC) study                | N/A                          | AIDS Clinical Trials Group | N/A   | CROI 2023, Abstracts <a href="#">392</a> , <a href="#">398</a><br><a href="#">J Infect Dis. jiad039.</a><br>HIV Persistence 2022, <a href="#">Abstract PP 7.8</a><br><a href="#">AIDS. 2022 Jun 23.</a><br><a href="#">FCIM 12:757846.</a><br><a href="#">J Infect Dis. 2022:jiac030</a><br>CROI 2021, <a href="#">Abstract 241</a> , <a href="#">Webcast</a><br>HIV Persistence 2019, Abstracts OP 4.6, 5.6 & PP 4.4 (see <a href="#">abstract book</a> )<br><a href="#">JAIDS. 81(5):594-599.</a><br>CROI 2018, <a href="#">Abstract 119</a> , <a href="#">Webcast</a><br><a href="#">Abstract 403LB</a><br><a href="#">PLoS Pathog. 13(9):e1006629.</a><br><a href="#">PLoS Pathog. 13(4): e1006285</a> |
| <b>ANRS CO24 OncoVIHAC:</b> Immune checkpoint inhibitors in HIV+ individuals with cancers                                                                | <a href="#">NCT03354936</a>  | Inserm-ANRS                | N/A   | <a href="#">Cells. 2022 Mar 17;11(6):1015.</a><br>AIDS 2020, <a href="#">Abstract OAB0203</a>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>ANRS EP 44:</b> Residual replication of HIV-1 in the gut associated lymphoid tissue (GALT)                                                            | <a href="#">NCT01038401</a>  | Inserm-ANRS                | N/A   | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>ANRS EP63:</b> A chronological study of the formation of HIV cellular reservoirs through the expression of surface markers on CD4+ T cell, inc. CD32a | <a href="#">NCT03298360</a>  | Inserm-ANRS                | N/A   | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                                       | Trial Registry Identifier(s)      | Manufacturer/ Sponsor(s)                                                                          | Phase | Published/Presented Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------|---------------------------------------------------------------------------------------------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>OBSERVATIONAL STUDIES (Cont.)</b>                                                                                        |                                   |                                                                                                   |       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>APACHE:</b> Monitored antiretroviral pause in chronically infected HIV+ individuals with long-lasting suppressed viremia | <a href="#">NCT03198325</a>       | Ospedale San Raffaele                                                                             | N/A   | <a href="#">PLoS One. 2022 Mar 15;17(3):e0265348.</a><br><a href="#">Viruses. 2021 Jul 19;13(7):1403.</a><br><a href="#">AIDS: May 14, 2021</a><br><a href="#">J Antimicrob Chemother. 2021 Mar 7:dkab060.</a><br><a href="#">J Antimicrob Chemother. 2020 Jun 15:dkaa231.</a><br>HIV Persistence 2019, <a href="#">Abstract PP 5.7.10</a><br><a href="#">J Antimicrob Chemother. 2019 April 23. pii: dkz138</a>                                                                                  |
| <b>ATN 147</b>                                                                                                              | <a href="#">ATN Cares website</a> | The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)                           | N/A   | CROI 2023, <a href="#">Abstract 457</a>                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>AVIR:</b> Characterization of HIV-1 reservoirs in adolescents with non-B HIV-1 on ART in Cameroon                        | <a href="#">NCT06363500</a>       | Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS | N/A   | <a href="#">J Virus Erad. 10(1):100367.</a>                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Biomarkers to predict time to plasma HIV RNA rebound (ACTG A5345)                                                           | <a href="#">NCT03001128</a>       | AIDS Clinical Trials Group                                                                        | N/A   | <a href="#">JID. 2024 Dec 11</a><br><a href="#">JCI Insight.9(3):e173864</a><br>CROI 2023, Abstracts <a href="#">337</a> , <a href="#">380</a><br>HIV Persistence Workshop 2022, <a href="#">Abstracts OP 7.3, PP 7.9 (slides)</a><br><a href="#">ARHR. 38(6):510-517</a><br>CROI 2022, <a href="#">Abstract 379</a><br><a href="#">Clin Infect Dis. 2021 Jun 12;ciab541.</a><br>CROI 2021, <a href="#">Abstract 311</a> , <a href="#">Webcast</a><br>AIDS 2020, <a href="#">Abstract PDB0102</a> |
| <b>CHERUB 003</b> (prospective HIV chemotherapy cohort study)                                                               | <a href="#">NCT01902693</a>       | Imperial College London/CHERUB                                                                    | N/A   | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                                                                           | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                                                                                      | Phase | Published/Presented Data                                                                                                                                                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>OBSERVATIONAL STUDIES (Cont.)</b>                                                                                                                            |                              |                                                                                                                               |       |                                                                                                                                                                                                             |
| <b>CLEAC:</b> Comparison of late versus early antiretroviral therapy in children with HIV                                                                       | <a href="#">NCT02674867</a>  | Inserm-ANRS                                                                                                                   | N/A   | <a href="#">Front Immunol. 2021 Apr 22;12:662894.</a><br><a href="#">Clin Infect Dis. ciaa1931</a><br>AIDS 2018, <a href="#">Abstract WEAB0208LB (slides)</a>                                               |
| <b>DOLUVOIR:</b> Cartography of virologic reservoir related to antiretroviral concentrations in HIV-1+ patients on first line treatment containing dolutegravir | <a href="#">NCT04133012</a>  | Inserm-ANRS                                                                                                                   | N/A   | N/A                                                                                                                                                                                                         |
| <b>EARTH:</b> Early antiretroviral treatment in children with HIV                                                                                               | <a href="#">NCT05784584</a>  | PENTA Foundation                                                                                                              | N/A   | <a href="#">eClinicalMedicine. May 23, 2024</a>                                                                                                                                                             |
| Effects of dolutegravir based regimen on HIV-1 reservoir and immune activation                                                                                  | <a href="#">NCT02557997</a>  | University Hospital, Strasbourg, France                                                                                       | N/A   | <a href="#">J Antimicrob Chemother. 2017 Dec 13.</a>                                                                                                                                                        |
| <b>EPIC4:</b> Early Pediatric Initiation: Canada Child cure Cohort Study                                                                                        | <a href="#">CTN S 281</a>    | Canadian Institutes of Health Research (CIHR)/Canadian Foundation for AIDS Research (CANFAR)/International AIDS Society (IAS) | N/A   | <a href="#">AIDS. 34(5):687-697</a><br><a href="#">Clin Infect Dis. pii: ciz251</a><br>AIDS 2014, <a href="#">Abstract TUAB0206LB (video)</a><br><a href="#">Clin Infect Dis. (2014) 59 (7): 1012-1019.</a> |
| Extended follow-up of the ISS T-003 trial volunteers (ISS T-003 EF-UP2020)                                                                                      | <a href="#">NCT05680948</a>  | Istituto Superiore di Sanità                                                                                                  | N/A   | AIDS 2024, <a href="#">Abstract OAA1303</a>                                                                                                                                                                 |
| <b>EURECA:</b> Exploratory study of cellular reservoirs in blood                                                                                                | <a href="#">NCT02858414</a>  | Centre Hospitalier Universitaire de Besancon                                                                                  | N/A   | <a href="#">Viruses. 2018 Apr 13;10(4).</a>                                                                                                                                                                 |
| Expectation, motivation, and experience of HIV+ patients regarding participation to an HIV cure-related clinical trial (AMEP-EHVA T02)                          | <a href="#">NCT05280392</a>  | ANRS                                                                                                                          | N/A   | <a href="#">ARHR 2024 Oct 22. doi: 10.1089/aid.2024.0064.</a>                                                                                                                                               |
| <b>FXReservoir:</b> Study of the effects of farnesoid X receptor ligands on reactivation of latent provirus                                                     | <a href="#">NCT03618862</a>  | Hospices Civils de Lyon                                                                                                       | N/A   | N/A                                                                                                                                                                                                         |
| Genotyping FcγRs genes                                                                                                                                          | <a href="#">NCT03130296</a>  | University Hospital, Strasbourg, France                                                                                       | N/A   | <a href="#">Genes Immun. 2020 Aug;21(4):263-268</a>                                                                                                                                                         |
| <b>HCURE:</b> Impact of HCV DAAs on antiviral immunity & HIV reservoir in HIV-HCV coinfection                                                                   | <a href="#">NCT03244371</a>  | Assistance Publique Hopitaux De Marseille                                                                                     | N/A   | N/A                                                                                                                                                                                                         |
| <b>HEATHER:</b> HIV reservoir targeting with early antiretroviral therapy                                                                                       | UK CPMS17589                 | University of Oxford/Medical Research Council/British HIV Association                                                         | N/A   | <a href="#">Front Imm. 15:1352123.</a><br><a href="#">Front Imm. 12:647688.</a><br><a href="#">J Infect Dis. pii: jiz563</a><br><a href="#">Mucosal Immunol. 12(5):1212-1219.</a>                           |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                                                      | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                 | Phase | Published/Presented Data                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------------------------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>OBSERVATIONAL STUDIES (Cont.)</b>                                                                                                       |                              |                                                          |       |                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>HIV-PRADA:</b> HIV persistence in lymph node and peripheral blood                                                                       | <a href="#">NCT03426189</a>  | University of Melbourne                                  | N/A   | <a href="#">Cell Rep Med. 2022 Sep 28:100766</a><br>CROI 2021, <a href="#">Abstract 301</a> , <a href="#">Webcast</a>                                                                                                                                                                                                                                                                      |
| HIV resistance and treatment strategies                                                                                                    | <a href="#">NCT00581802</a>  | NIAID                                                    | N/A   | N/A                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>HIV-STAR:</b> HIV sequencing after treatment interruption to identify the clinically relevant anatomical reservoir                      | <a href="#">NCT02641756</a>  | University Hospital, Ghent                               | N/A   | <a href="#">Cell Rep. 39(4):110739</a> .<br>IAS 2021, <a href="#">Abstract PEA036</a> (poster, video)<br><a href="#">J Virus Erad. 2021 Jan 23;7(1):100029</a> .<br>CROI 2020, <a href="#">Abstract 324</a><br><a href="#">Cell Host Microbe. 2019 Sep 11;26(3):347-358.e7</a> .<br>AIDS 2018, Abstract <a href="#">WEAA0201</a> (slides, video), poster abstract <a href="#">THPEB096</a> |
| Host & viral factors associated with HIV elite control                                                                                     | UK CPMS16146                 | University College London Hospitals NHS Foundation Trust | N/A   | N/A                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>HSCT-HIV:</b> Allogeneic hematopoietic stem cell transplantation in HIV+ patients                                                       | <a href="#">NCT02732457</a>  | Kirby Institute                                          | N/A   | Terminated by Protocol Steering Committee                                                                                                                                                                                                                                                                                                                                                  |
| HUSH restriction in HIV+ patients                                                                                                          | <a href="#">NCT04172480</a>  | Inserm-ANRS                                              | N/A   | N/A                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>ImmunoCo27:</b> Co-adaptation between HIV and CD8 cellular immunity                                                                     | <a href="#">NCT02886416</a>  | Inserm-ANRS                                              | N/A   | N/A                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>IMPAACT 2015:</b> Evaluation of the HIV-1 reservoir in the CNS of perinatally-infected youth and young adults with cognitive impairment | <a href="#">NCT03416790</a>  | IMPAACT                                                  | N/A   | <a href="#">AIDS. 2024 May 29</a> .                                                                                                                                                                                                                                                                                                                                                        |
| Impact of ART adherence on HIV persistence and inflammation                                                                                | <a href="#">NCT02797093</a>  | University of Colorado, Denver                           | N/A   | N/A                                                                                                                                                                                                                                                                                                                                                                                        |
| Impact of a short-term ATI and re-initiation of antiretroviral therapy on immunologic and virologic parameters in HIV+ individuals         | <a href="#">NCT03225118</a>  | NIAID                                                    | N/A   | <a href="#">J Infect Dis. 2020 May 22:jiaa270</a> .                                                                                                                                                                                                                                                                                                                                        |
| In vitro autologous vaccine development to activate HIV reservoirs                                                                         | UK CPMS17532                 | Imperial College London/amfAR                            | N/A   | N/A                                                                                                                                                                                                                                                                                                                                                                                        |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                | Trial Registry Identifier(s)     | Manufacturer/ Sponsor(s)                                                                                                                     | Phase | Published/Presented Data                                                                                                                                                                                                                                                                                                                                                                 |
|------------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>OBSERVATIONAL STUDIES (Cont.)</b>                                                                 |                                  |                                                                                                                                              |       |                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>ISALA:</b> Analytical treatment interruption                                                      | <a href="#">NCT02590354</a>      | Institute of Tropical Medicine, Belgium                                                                                                      | N/A   | <a href="#">Strategies for an HIV Cure 2023, Abstract PP20</a><br><a href="#">IAS 2023, Abstract TUPEA07</a><br><a href="#">J Int AIDS Soc. 2020 Feb;23(2):e25453.</a><br><a href="#">CROI 2019, Poster abstract 389, Webcast</a>                                                                                                                                                        |
| Long-term effects of ART in acute HIV infection                                                      | <a href="#">ChiCTR1800015006</a> | Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, The First Affiliated Hospital, China Medical University | N/A   | N/A                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>LoViReT:</b> Low viral reservoir treated patients                                                 | <a href="#">NCT02972931</a>      | IrsiCaixa                                                                                                                                    | N/A   | <a href="#">HIV Persistence Workshop 2022, Abstract PP 3.13</a><br><a href="#">J Intern Med. 2022 Mar 28.</a><br><a href="#">EBioMedicine. 2020 Jun 21;57:102830.</a><br><a href="#">CROI 2020, Abstract 374</a><br><a href="#">HIV Persistence Workshop 2019, Abstract OP 3.5 (see <a href="#">abstract book</a>)</a><br><a href="#">HIV Persistence Workshop 2017, Abstract OP 8.6</a> |
| Measurement for viral reservoir and immune function in HIV-1+ patients under antiretroviral therapy  | <a href="#">NCT04068441</a>      | National Taiwan University Hospital                                                                                                          | N/A   | <a href="#">JAIDS. 86(4):500-508</a>                                                                                                                                                                                                                                                                                                                                                     |
| <b>MUCOVIR:</b> Exploration of HIV reservoirs                                                        | <a href="#">NCT01019044</a>      | Objectif Recherche Vaccins SIDA                                                                                                              | N/A   | <a href="#">JAIDS. 62(3):255–9</a>                                                                                                                                                                                                                                                                                                                                                       |
| <b>PembroHIV:</b> Treatment with immunological checkpoint inhibitors of HIV+ individuals with cancer | <a href="#">NCT03767465</a>      | IrsiCaixa                                                                                                                                    | N/A   | <a href="#">HIV Persistence Workshop 2019, Abstract PP 4.2 (see <a href="#">abstract book</a>)</a>                                                                                                                                                                                                                                                                                       |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                       | Trial Registry Identifier(s)                                                                  | Manufacturer/ Sponsor(s)                                                              | Phase | Published/Presented Data                                                                                                                                                                                                                                                                                         |
|-------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>OBSERVATIONAL STUDIES (Cont.)</b>                                                                        |                                                                                               |                                                                                       |       |                                                                                                                                                                                                                                                                                                                  |
| <b>PITCH:</b> Prospective interruption of therapy towards a cure for HIV pilot study                        | <a href="#">NHS Health Research Authority approval</a> (not entered into any online registry) | University of Oxford                                                                  | N/A   | <a href="#">Eur J Immunol. 2024 Aug 13:e2451200.</a><br>CROI 2022, <a href="#">Abstract 266</a><br>BHIVA Digital Conference, Nov 22–24, 2020, <a href="#">Abstract P22</a>                                                                                                                                       |
| Quantification of antisense HIV RNA                                                                         | <a href="#">NCT05381844</a>                                                                   | Institut National de la Santé Et de la Recherche Médicale                             | N/A   | N/A                                                                                                                                                                                                                                                                                                              |
| Quantitative measurement and correlates of the latent HIV reservoir in virally suppressed Ugandans          | <a href="#">NCT02154035</a>                                                                   | NIAID                                                                                 | N/A   | <a href="#">EBioMedicine. 105040.</a><br><a href="#">Virus Evol. 2023 Jul 27;9(2):vead046.</a><br><a href="#">JCI Insight. 139287.</a><br>CROI 2020, <a href="#">Abstract 385</a><br>Persistence Workshop 2019, <a href="#">Abstract OP 7.4</a><br><a href="#">Clin Infect Dis. 2017 Oct 15;65(8):1308-1315.</a> |
| Role of anti-Tat immunity on disease progression in HIV+ asymptomatic adults                                | <a href="#">NCT01029548</a>                                                                   | National HIV/AIDS Research Center (CNAIDS), Istituto Superiore di Sanità, Rome, Italy | N/A   | <a href="#">Retrovirology. 2014 Jun 24;11:49.</a>                                                                                                                                                                                                                                                                |
| Role of anti-Tat immunity on disease progression in HIV+ cART-treated adults                                | <a href="#">NCT01024556</a>                                                                   | CNAIDS, Istituto Superiore di Sanità, Rome, Italy                                     | N/A   | <a href="#">EBioMedicine 00 (2021) 103306</a>                                                                                                                                                                                                                                                                    |
| Role of the IL-33/amphiregulin pathway as a potential therapeutic target in HIV infection                   | <a href="#">NCT03622177</a>                                                                   | Inserm-ANRS                                                                           | N/A   | <a href="#">J Immunol. 2022 May 2;ji2100725.</a>                                                                                                                                                                                                                                                                 |
| Seroprevalence of anti-Tat antibodies in South African people with HIV                                      | <a href="#">NCT01359800</a>                                                                   | CNAIDS, Istituto Superiore di Sanità, Rome, Italy                                     | N/A   | N/A                                                                                                                                                                                                                                                                                                              |
| Size of the HIV-1 reservoir and ongoing replication in defined cohorts                                      | UK CPMS16004                                                                                  | University College London/amfAR                                                       | N/A   | N/A                                                                                                                                                                                                                                                                                                              |
| Specimen repository for HIV immunopathogenesis                                                              | <a href="#">NCT03579381</a>                                                                   | AIDS Healthcare Foundation                                                            | N/A   | N/A                                                                                                                                                                                                                                                                                                              |
| Tissue drug levels of HIV medications                                                                       | <a href="#">NCT01490346</a>                                                                   | University of Minnesota – Clinical and Translational Science Institute/NIAID          | N/A   | <a href="#">Proc Natl Acad Sci USA. 2014 Feb 11;111(6):2307-12.</a>                                                                                                                                                                                                                                              |
| <b>ULTRASTOP</b> (Towards HIV Functional Cure)<br><b>ERAMUNE-03</b> (antiretroviral treatment interruption) | <a href="#">NCT01876862</a>                                                                   | Objectif Recherche VACcin Sida (ORVACS)/Fondation Bettencourt Schueller               | N/A   | <a href="#">AIDS, Published Ahead-of-Print, January 4, 2016</a>                                                                                                                                                                                                                                                  |
| <b>VIRECT:</b> Impact of pre-ART CD4 T cell level on the rectal reservoir in long-term HIV-1 treated men    | <a href="#">NCT02526940</a>                                                                   | Centre Hospitalier Universitaire de Saint Etienne                                     | N/A   | N/A                                                                                                                                                                                                                                                                                                              |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                                                       | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                                                                            | Phase    | Published/Presented Data                                                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|---------------------------------------------------------------------------------------------------------------------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>PROTEASOME INHIBITORS</b>                                                                                                                |                              |                                                                                                                     |          |                                                                                                                                                               |
| <b>ixazomib</b>                                                                                                                             | <a href="#">NCT02946047</a>  | Mayo Clinic                                                                                                         | Phase I  | <a href="#">EClinicalMedicine 42:101225.</a>                                                                                                                  |
| <b>STEM CELL TRANSPLANTATION</b>                                                                                                            |                              |                                                                                                                     |          |                                                                                                                                                               |
| <b>HIVECT:</b> HIV eradication through cord-blood transplantation                                                                           | <a href="#">NCT02923076</a>  | Puerta de Hierro University Hospital                                                                                | N/A      | N/A                                                                                                                                                           |
| <b>IMPAACT P1107:</b> Cord blood transplantation using CCR5-Δ32 donor cells for the treatment of HIV and underlying disease                 | <a href="#">NCT02140944</a>  | International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)                                    | N/A      | <a href="#">Cell. 2023 Mar 16;186(6):1115-1126.e8.</a><br><a href="#">CROI 2022, Abstract 65</a><br><a href="#">ASH 2018, Abstract 2184</a>                   |
| Cord blood transplant with OTS for the treatment of HIV+ hematologic cancers                                                                | <a href="#">NCT04083170</a>  | Fred Hutchinson Cancer Research Center                                                                              | Phase II | <a href="#">Study stopped</a> due to end of funding and lack of accrual                                                                                       |
| <b>BMT CTN 0903:</b> Allogeneic transplant in individuals with chemotherapy-sensitive hematologic malignancies and coincident HIV infection | <a href="#">NCT01410344</a>  | National Heart, Lung, & Blood Institute/National Cancer Institute/Blood & Marrow Transplant Clinical Trials Network | Phase II | <a href="#">Biol Blood Marrow Transplant. 2019 Jul 4. pii: S1083-8791(19)30417-3.</a><br><a href="#">J Clin Oncol. 35, no. 15 suppl (May 2017) 7006-7006.</a> |
| HLA-mismatched unrelated donor bone marrow transplantation                                                                                  | <a href="#">NCT02793544</a>  | Center for International Blood and Marrow Transplant Research                                                       | Phase II | <a href="#">HRSA Advisory Council on Blood Stem Cell Transplantation, September 25, 2020</a>                                                                  |
| Immune response after stem cell transplant in HIV-positive patients with hematologic cancer                                                 | <a href="#">NCT00968630</a>  | Fred Hutchinson Cancer Research Center                                                                              | Phase II | N/A                                                                                                                                                           |
| Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-1 individuals                             | <a href="#">NCT01836068</a>  | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins                                                          | Phase I  | <a href="#">JAIDS 2021 Nov 8. AIDS Res Hum Retroviruses. 2021 Jun 9.</a><br><a href="#">Lancet HIV. 2020 Jul 7: S2352-3018(20)30073-4.</a>                    |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                        | Trial Registry Identifier(s)                                                          | Manufacturer/ Sponsor(s)                          | Phase      | Published/Presented Data                                                                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>STIMULANTS</b>                                                                                            |                                                                                       |                                                   |            |                                                                                                                                                                                                 |
| <b>EMRLHD:</b> Effect of methamphetamine on residual latent HIV disease study                                | <a href="#">NCT03825536</a>                                                           | University of California, San Francisco           | Phase IV   | N/A                                                                                                                                                                                             |
| <b>TARGETED ACTIVATOR OF CELL KILL (TACK) MOLECULES</b>                                                      |                                                                                       |                                                   |            |                                                                                                                                                                                                 |
| <b>MK-4646</b>                                                                                               | <a href="#">2024-510899-20-00</a>                                                     | Merck Sharp & Dohme LLC                           | Phase I    | N/A                                                                                                                                                                                             |
| <b>T-CELL RECEPTOR-BASED BISPECIFICS</b>                                                                     |                                                                                       |                                                   |            |                                                                                                                                                                                                 |
| <b>IMC-M113V</b> in HLA-A*02:01 positive people                                                              | IMC-M113V-101                                                                         | Immunocore                                        | Phase I/II | CROI 2023, <a href="#">Abstract 436</a>                                                                                                                                                         |
| <b>THERAPEUTIC VACCINES</b>                                                                                  |                                                                                       |                                                   |            |                                                                                                                                                                                                 |
| <b>AGS-004</b> (personalized therapeutic vaccine utilizing patient-derived dendritic cells and HIV antigens) | <a href="#">NCT00672191</a>                                                           | Argos Therapeutics                                | Phase IIb  | <a href="#">JAIDS. 2016 May 1;72(1):31-8</a>                                                                                                                                                    |
| <b>AGS-004</b>                                                                                               | <a href="#">NCT01069809</a>                                                           | Argos Therapeutics                                | Phase IIb  | <a href="#">ARHR. 34(1):111-122</a><br>CROI 2014, <a href="#">Poster abstract 344</a>                                                                                                           |
| <b>iHIVARNA-01</b> (TriMix & HIV antigen naked messenger RNA)                                                | <a href="#">NCT02888756</a>                                                           | Rob Gruters, Erasmus Medical Center               | Phase IIa  | <a href="#">Vaccines (Basel). 7(4). pii: E209.</a>                                                                                                                                              |
| <b>DermaVir</b> (topically applied DNA vaccine)                                                              | <a href="#">NCT00711230</a>                                                           | Genetic Immunity                                  | Phase II   | N/A                                                                                                                                                                                             |
| <b>DermaVir</b>                                                                                              | <a href="#">NCT00918840</a>                                                           | Genetic Immunity                                  | Phase II   | N/A                                                                                                                                                                                             |
| <b>GSK Biologicals HIV Vaccine 732462</b> (p24-RT-Nef-p17 fusion protein vaccine)                            | <a href="#">NCT01218113</a>                                                           | GlaxoSmithKline                                   | Phase II   | <a href="#">Medicine (Baltimore). 2016 Feb;95(6):e2673</a>                                                                                                                                      |
| <b>GTU-multiHIV + LIPO-5</b> (DNA + lipopeptide vaccines)                                                    | <a href="#">NCT01492985</a>                                                           | Inserm-ANRS                                       | Phase II   | <a href="#">J Virol. 2021 May; 95(9): e02165-20.</a><br><a href="#">J Infect Dis. 2019 Jul 2;220:S5-S6</a><br><a href="#">AIDS. 2018 Oct 15</a><br><a href="#">HIVR4P 2016, Abstract P27.09</a> |
| <b>Tat protein vaccine</b>                                                                                   | <a href="#">NCT01513135</a><br><a href="#">NCT02712489</a> (extended follow-up study) | CNAIDS, Istituto Superiore di Sanità, Rome, Italy | Phase II   | <a href="#">Retrovirology. 2016 Jun 9;13(1):34</a>                                                                                                                                              |
| <b>Tat protein vaccine</b>                                                                                   | <a href="#">NCT00751595</a><br><a href="#">NCT02118168</a> (extended follow-up study) | Barbara Ensoli, MD, Istituto Superiore di Sanità  | Phase II   | <a href="#">Front. Immunol. February 13, 2019</a><br><a href="#">Retrovirology. 2015 Apr 29;12(1):33</a><br><a href="#">PLoS One. 2010 Nov 11;5(11):e13540</a>                                  |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                              | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                                                                | Phase       | Published/Presented Data                                                                                                  |
|--------------------------------------------------------------------|------------------------------|---------------------------------------------------------------------------------------------------------|-------------|---------------------------------------------------------------------------------------------------------------------------|
| <b>THERAPEUTIC VACCINES (Cont.)</b>                                |                              |                                                                                                         |             |                                                                                                                           |
| <b>Vacc-4x</b> (peptide-based vaccine)                             | <a href="#">NCT01712256</a>  | Bionor Immuno AS                                                                                        | Phase II    | <a href="#">PLoS One. 2019 Jan 30;14(1):e0210965.</a>                                                                     |
| <b>Vacc-4x</b>                                                     | <a href="#">NCT00659789</a>  | Bionor Immuno AS                                                                                        | Phase II    | <a href="#">Lancet Infect Dis. 2014 Apr;14(4):291-300</a>                                                                 |
| <b>VAC-3S</b> (peptide-based vaccine)                              | <a href="#">NCT02041247</a>  | InnaVirVax                                                                                              | Phase II    | <a href="#">NPJ Vaccines (2019) 4:1</a><br>IAS 2017, Abstract MOSY0404 ( <a href="#">slides</a> , <a href="#">video</a> ) |
| <b>VAC-3S</b>                                                      | <a href="#">NCT02390466</a>  | InnaVirVax                                                                                              | Phase I/IIa | N/A                                                                                                                       |
| <b>VAC-3S</b> (peptide-based vaccine)                              | <a href="#">NCT01549119</a>  | InnaVirVax                                                                                              | Phase I/IIa | 30 Years of HIV Science, 2013, <a href="#">Poster abstract 145</a>                                                        |
| <b>AGS-004</b>                                                     | <a href="#">NCT02042248</a>  | University of North Carolina at Chapel Hill/Argos Therapeutics/U.S. National Institutes of Health (NIH) | Phase I/II  | N/A                                                                                                                       |
| <b>Autologous HIV-1 ApB DC Vaccine</b>                             | <a href="#">NCT00510497</a>  | Sharon Riddler, University of Pittsburgh/NIAID                                                          | Phase I/II  | <a href="#">J Infect Dis. 2016 May 1;213(9):1400-9</a>                                                                    |
| <b>Dendritic cells pulsed with chemically inactivated HIV</b>      | <a href="#">NCT02766049</a>  | University of Sao Paulo General Hospital                                                                | Phase I/II  | <a href="#">J. Cellular Immunotherapy xx (2016) 1-10</a><br><a href="#">J Int AIDS Soc. 2014 Jan 10;17:18938</a>          |
| <b>Dendritic cell vaccine</b>                                      | <a href="#">NCT00833781</a>  | Massachusetts General Hospital                                                                          | Phase I/II  | <a href="#">JAIDS 71(3):246-53.</a>                                                                                       |
| <b>Dendritic cell vaccine (DCV-2)</b>                              | <a href="#">NCT00402142</a>  | Hospital Clinic of Barcelona                                                                            | Phase I/II  | <a href="#">Sci Transl Med. 2013 Jan 2;5(166):166ra2</a>                                                                  |
| <b>DermaVir</b>                                                    | <a href="#">NCT00270205</a>  | AIDS Clinical Trials Group                                                                              | Phase I/II  | <a href="#">JAIDS. 2013 Dec 1;64(4):351-9</a>                                                                             |
| <b>GTU®-MultiHIV B clade vaccine</b>                               | <a href="#">NCT02457689</a>  | Imperial College London                                                                                 | Phase I/II  | <a href="#">Front Immunol. 2019 Dec 13;10:2911.</a>                                                                       |
| <b>p24CE1/2 + p55<sup>gag</sup> conserved-element DNA vaccines</b> | <a href="#">NCT03560258</a>  | NIAID                                                                                                   | Phase I/II  | <a href="#">AIDS. 2023 Dec 4.</a>                                                                                         |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                                                                                                        | Phase      | Published/Presented Data                                                                                                                                                                                                                                               |
|------------------------------------------------------------------------------------------------------|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>THERAPEUTIC VACCINES (Cont.)</b>                                                                  |                              |                                                                                                                                                 |            |                                                                                                                                                                                                                                                                        |
| <b>PENNVAX-GP or INO-6145 + IL-12 DNA adjuvant (INO-9012)</b> (DNA vaccines)                         | <a href="#">NCT03606213</a>  | Steven Deeks, UCSF                                                                                                                              | Phase I/II | CROI 2025, <a href="#">Abstract 142</a><br>HIVR4P 2024, <a href="#">Abstract OA0302</a><br>CROI 2023, Abstracts <a href="#">408</a> , <a href="#">428</a><br>HIV Persistence Workshop 2022, <a href="#">Abstract PP 8.3</a><br>CROI 2022, <a href="#">Abstract 284</a> |
| <b>Tat Oyi</b> (protein-based vaccine)                                                               | <a href="#">NCT01793818</a>  | Biosantech                                                                                                                                      | Phase I/II | <a href="#">Retrovirology. 2016 Apr 1;13:21</a>                                                                                                                                                                                                                        |
| <b>THV01</b> (lentiviral vector-based therapeutic vaccine)                                           | <a href="#">NCT02054286</a>  | Theravectys S.A.                                                                                                                                | Phase I/II | N/A                                                                                                                                                                                                                                                                    |
| <b>TUTI-16</b> (synthetic HIV-1 Tat epitope vaccine)                                                 | <a href="#">NCT01335191</a>  | Thymon, LLC                                                                                                                                     | Phase I/II | <a href="#">Hum Vaccin Immunother. 2012 Oct;8(10):1425-30</a>                                                                                                                                                                                                          |
| <b>Vacc-C5</b> (peptide-based vaccine)                                                               | <a href="#">NCT01627678</a>  | Bionor Immuno AS                                                                                                                                | Phase I/II | <a href="#">JAIDS 77:57</a><br><a href="#">BMC Infect Dis. 2017 Mar 24;17(1):228</a>                                                                                                                                                                                   |
| <b>Ad26.Mos4.HIV + MVA-Mosaic or clade C gp140 + mosaic gp140</b> (viral vector vaccines + proteins) | <a href="#">NCT03307915</a>  | Janssen Vaccines & Prevention B.V.                                                                                                              | Phase I    | <a href="#">NPJ Vaccines. 9(1):89.</a>                                                                                                                                                                                                                                 |
| <b>Ad26.Mos.HIV + MVA-Mosaic</b>                                                                     | <a href="#">NCT02919306</a>  | Janssen Vaccines & Prevention B.V.                                                                                                              | Phase I    | <a href="#">Clin Infect Dis. 73(7):e1885-e1892.</a><br><a href="#">Cell Rep. 43(6):114344.</a><br>HIV Persistence Workshop 2022, <a href="#">Abstract PP 8.6</a><br><a href="#">Nat Med March 23, 2020.</a>                                                            |
| <b>AFO-18</b> (peptide-based vaccine)                                                                | <a href="#">NCT01141205</a>  | Statens Serum Institut (SSI)/Ministry of the Interior and Health, Denmark/European and Developing Countries Clinical Trials Partnership (EDCTP) | Phase I    | <a href="#">AIDS Res Hum Retroviruses. 2013 Nov;29(11):1504-12</a>                                                                                                                                                                                                     |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                    | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                                                            | Phase   | Published/Presented Data                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------|------------------------------|-----------------------------------------------------------------------------------------------------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>THERAPEUTIC VACCINES (Cont.)</b>                                                                      |                              |                                                                                                     |         |                                                                                                                                                                                     |
| <b>AFO-18</b> (peptide-based vaccine)                                                                    | <a href="#">NCT01009762</a>  | SSI/Rigshospitalet/Hvidovre University Hosp./Ministry of Interior & Health, Denmark                 | Phase I | <a href="#">Clin Immunol. 2013 Feb;146(2):120-30</a>                                                                                                                                |
| <b>AT20-KLH</b>                                                                                          | MED-AT20-001                 | Medestea Research & Production SpA, Turin                                                           | Phase I | <a href="#">Vaccine. 32(9):1072-8</a>                                                                                                                                               |
| <b>ChAdOx1.HIVconsv62-MVA.tHIVconsv4 (C62-M4), ChAdOx1.tHIVconsv1+C62-MVA.tHIVconsv3+M4 (C1C62-M3m4)</b> | <a href="#">NCT05604209</a>  | University of North Carolina, Chapel Hill                                                           | Phase I | N/A                                                                                                                                                                                 |
| <b>ChAdOx1.HTI, MVA.HTI, ConM SOSIP.v7 gp140</b>                                                         | <a href="#">NCT05208125</a>  | IrsiCaixa                                                                                           | Phase I | N/A                                                                                                                                                                                 |
| <b>ChAdV63.HIVconsv + MVA.HIVconsv</b> (viral vector vaccines)                                           | <a href="#">NCT01712425</a>  | IrsiCaixa/Fundació Lluita contra la SIDA/Hospital Clinic of Barcelona/ HIVACAT/University of Oxford | Phase I | <a href="#">EClinicalMedicine. 2019 Jun 5;11:65-80.</a><br>IAS 2015, <a href="#">Poster abstract MOPEA036</a>                                                                       |
| <b>DC-HIV04:</b> a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides                  | <a href="#">NCT03758625</a>  | Sharon Riddler, University of Pittsburgh                                                            | Phase I | N/A                                                                                                                                                                                 |
| <b>Dendritic cells loaded with HIV-1 lipopeptides</b>                                                    | <a href="#">NCT00796770</a>  | Baylor Research Institute/ANRS                                                                      | Phase I | <a href="#">PLoS Pathog. 2019 15(9):e1008011.</a><br><a href="#">Eur J Immunol. 2014 Sep;44(9):2802-10.</a><br><a href="#">Retrovirology 2012, 9(Suppl 2):P328</a>                  |
| <b>DermaVir</b>                                                                                          | <a href="#">NCT00712530</a>  | Genetic Immunity                                                                                    | Phase I | <a href="#">PLoS One. 2012 7(5): e35416</a>                                                                                                                                         |
| <b>D-GPE DNA + M-GPE MVA</b> (DNA + viral vector vaccines)                                               | <a href="#">NCT01881581</a>  | Centers for Disease Control and Prevention, China                                                   | Phase I | N/A                                                                                                                                                                                 |
| <b>DNA.HTI + MVA.HTI + ChAdOx1.HTI</b> (DNA + viral vector vaccines) (ATI extension)                     | <a href="#">NCT04385875</a>  | Fundacio Lluita Contra la SIDA                                                                      | Phase I | N/A                                                                                                                                                                                 |
| <b>DNA.HTI + MVA.HTI + ChAdOx1.HTI</b> (DNA + viral vector vaccines)                                     | <a href="#">NCT03204617</a>  | Aelix Therapeutics                                                                                  | Phase I | HIV Persistence Workshop 2022, <a href="#">Abstract OP 8.3 (slides)</a><br><a href="#">Nat Med 2022 Oct 27</a><br>CROI 2021, <a href="#">Abstract 161</a> , <a href="#">Webcast</a> |
| <b>HIVAX</b> (lentiviral vector-based therapeutic vaccine)                                               | <a href="#">NCT01428596</a>  | GeneCure Biotechnologies                                                                            | Phase I | <a href="#">Vaccine. 2020;S0264-410X(20)30485-0</a><br><a href="#">Vaccine. 2016;34(19):2225-32</a>                                                                                 |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                       | Trial Registry Identifier(s)                                                          | Manufacturer/ Sponsor(s)                                   | Phase   | Published/Presented Data                                                                                                                                                   |
|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------|------------------------------------------------------------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>THERAPEUTIC VACCINES (Cont.)</b>                                         |                                                                                       |                                                            |         |                                                                                                                                                                            |
| <b>HIV-v</b> (peptide-based vaccine)                                        | <a href="#">NCT01071031</a>                                                           | PepTcell Limited                                           | Phase I | <a href="#">Vaccine. 2013 Nov 19;31(48):5680–6</a>                                                                                                                         |
| <b>iHIVARNA-01</b> (TriMix & HIV antigen naked messenger RNA)               | <a href="#">NCT02413645</a>                                                           | Biomedical Research Institute August Pi i Sunyer (IDIBAPS) | Phase I | <a href="#">AIDS. 2018 Nov 13;32(17):2533–2545.</a>                                                                                                                        |
| <b>JS7 DNA + MVA62B</b> (DNA + viral vector vaccines)                       | <a href="#">NCT01378156</a>                                                           | GeoVax, Inc.                                               | Phase I | <a href="#">PLoS One. 2016 Oct 6;11(10):e0163164</a>                                                                                                                       |
| <b>MAG pDNA vaccine +/- IL-12</b>                                           | <a href="#">NCT01266616</a>                                                           | NIAID                                                      | Phase I | <a href="#">JAIDS. 2016 Feb 1;71(2):163-71.</a>                                                                                                                            |
| <b>MAG-pDNA + rVSV<sub>IN</sub> HIV-1 Gag</b> (DNA + viral vector vaccines) | <a href="#">NCT01859325</a>                                                           | NIAID/Profectus Biosciences, Inc.                          | Phase I | <a href="#">J. Virology May 20, 2020</a><br><a href="#">CROI 2019, Poster abstract 392</a><br><a href="#">Sci Transl Med. 2017 Dec 6;9(419). pii: eaan8848</a>             |
| <b>MVA.HIVconsv</b>                                                         | <a href="#">NCT01024842</a>                                                           | University of Oxford/Medical Research Council              | Phase I | <a href="#">J Int AIDS Soc. 2017 May 19;20(1):21171.</a>                                                                                                                   |
| <b>MVA.tHIVconsv3 +/- MVA.tHIVconsv4</b> (viral vectors)                    | <a href="#">NCT03844386</a>                                                           | University of North Carolina, Chapel Hill                  | Phase I | <a href="#">Results posted in clinicaltrials.gov</a>                                                                                                                       |
| <b>PENNVAX-B (Gag, Pol, Env) + electroporation</b>                          | <a href="#">NCT01082692</a>                                                           | Inovio Pharmaceuticals                                     | Phase I | <a href="#">Retrovirology 2012, 9(Suppl 2):P276</a>                                                                                                                        |
| <b>PENNVAX-B +/- IL-12 or IL-15</b>                                         | <a href="#">NCT00775424</a>                                                           | University of Pennsylvania                                 | Phase I | N/A                                                                                                                                                                        |
| Recombinant adenovirus type 5 vaccine                                       | <a href="#">NCT02762045</a>                                                           | China CDC                                                  | Phase I | N/A                                                                                                                                                                        |
| <b>rMVA-HIV + rFPV-HIV</b> (viral vector vaccines) in young adults          | <a href="#">NCT00107549</a>                                                           | NIAID                                                      | Phase I | <a href="#">AIDS. 2011 Nov 28; 25(18): 2227–2234</a>                                                                                                                       |
| <b>Tat protein vaccine</b>                                                  | <a href="#">NCT00505401</a><br><a href="#">NCT01024595</a> (extended follow-up study) | CNAIDS, Istituto Superiore di Sanità, Rome, Italy          | Phase I | <a href="#">Rev Recent Clin Trials. 2009 Sep;4(3):195-204</a><br><a href="#">Vaccine. 2009 May 26;27(25-26):3306-12</a><br><a href="#">AIDS. 2008 Oct 18;22(16):2207-9</a> |
| Therapeutic vaccine based on aDC1 dendritic cells                           | <a href="#">NCT05786937</a>                                                           | University of Sao Paulo General Hospital                   | Phase I | “Unknown status”                                                                                                                                                           |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                            | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                            | Phase        | Published/Presented Data                                                                                                                                                                                                                                                                                                                                                                                                                      |
|------------------------------------------------------------------|------------------------------|-----------------------------------------------------|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>TOLL-LIKE RECEPTOR AGONISTS</b>                               |                              |                                                     |              |                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>MGN1703</b> toll-like receptor 9 (TLR9) agonist               | <a href="#">NCT02443935</a>  | University of Aarhus                                | Phase Ib/Ila | <a href="#">EBioMedicine. 2019 Jul 9. pii: S2352-3964(19)30440-2.</a><br><a href="#">AIDS. 2019 Mar 29</a><br><a href="#">CID. 2017 Mar 9</a>                                                                                                                                                                                                                                                                                                 |
| <b>Poly-ICLC</b> (TLR3 agonist)                                  | <a href="#">NCT02071095</a>  | Nina Bhardwaj, MD/Campbell Foundation/Oncovir, Inc. | Phase I/II   | <a href="#">Front Immunol. 2019 Apr 9;10:725.</a>                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>vesatolimod</b> (TLR7 agonist) in ART-treated HIV controllers | <a href="#">NCT03060447</a>  | Gilead Sciences                                     | Phase Ib     | <a href="#">Front Immunol. 15:1405348.</a><br><a href="#">Eur J Immunol. e2350809.</a><br>Strategies for an HIV Cure 2023, <a href="#">Abstract PP24</a><br>CROI 2023, <a href="#">Abstract 437</a><br><a href="#">EACS 2021</a> , Abstract PE2/1<br>IAS 2021, <a href="#">Abstract OAA0304 (video)</a><br><a href="#">Sci Transl Med. 2021 Jun 23;13(599): eabg3071.</a><br>CROI 2020, <a href="#">Abstract 40</a> , <a href="#">Webcast</a> |
| <b>vesatolimod</b> (formerly GS-9620) (TLR7 agonist)             | <a href="#">NCT02858401</a>  | Gilead Sciences                                     | Phase Ib     | <a href="#">Eur J Immunol. e2350809.</a><br>CROI 2024, <a href="#">Abstract 542</a><br><a href="#">CID. c1aa1534</a><br>IAS 2019, <a href="#">Abstract WEAA0304 (slides)</a>                                                                                                                                                                                                                                                                  |
| <b>vesatolimod</b> (TLR7 agonist drug interaction study)         | <a href="#">NCT05458102</a>  | Gilead Sciences                                     | Phase I      | Terminated: Sponsor decision to change the clinical development plan (not based on efficacy or safety concerns)                                                                                                                                                                                                                                                                                                                               |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                                                     | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                   | Phase      | Published/Presented Data                                                                                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>TRADITIONAL CHINESE MEDICINE</b>                                                                                                       |                              |                                                            |            |                                                                                                                                                                                                |
| <b>Triptolide wilfordii</b>                                                                                                               | <a href="#">NCT02219672</a>  | Peking Union Medical College                               | Phase III  | N/A                                                                                                                                                                                            |
| <b>TREATMENT INTENSIFICATION/EARLY TREATMENT</b>                                                                                          |                              |                                                            |            |                                                                                                                                                                                                |
| <b>enfuvirtide</b>                                                                                                                        | <a href="#">NCT00051831</a>  | NIAID                                                      | Not listed | <a href="#">J Infect Dis. 2010 Jan 15;201(2):293–6</a>                                                                                                                                         |
| <b>enfuvirtide</b>                                                                                                                        | <a href="#">NCT00334022</a>  | Canadian Immunodeficiency Research Collaborative           | Not listed | N/A                                                                                                                                                                                            |
| <b>New Era Study:</b> Treatment with multi–drug class (MDC) HAART                                                                         | <a href="#">NCT00908544</a>  | MUC Research GmbH                                          | Not listed | <a href="#">Front Immunol. 2018 Apr 30;9:811</a>                                                                                                                                               |
| <b>PLUS:</b> Pilot study on the effect of adding raltegravir +/- a second drug on HIV levels in the gut                                   | <a href="#">NCT00884793</a>  | University of California, San Francisco                    | Not listed | <a href="#">J Infect Dis. 2010 Nov 15;202(10):1553–61</a><br><a href="#">AIDS. 2010 Oct 23;24(16):2451–60</a>                                                                                  |
| Anti-HIV medications for people with recent HIV acquisition                                                                               | <a href="#">NCT00106171</a>  | NIAID                                                      | Phase IV   | <a href="#">PLoS One. 2015 10(11):e0143259</a>                                                                                                                                                 |
| Antiretroviral regime for viral eradication in newborns                                                                                   | <a href="#">NCT02712801</a>  | National Center for Women and Children's Health, China CDC | Phase IV   | N/A                                                                                                                                                                                            |
| <b>DIORR:</b> Dolutegravir impact on residual replication                                                                                 | <a href="#">NCT02500446</a>  | University of Melbourne                                    | Phase IV   | <a href="#">The Lancet HIV, April 8, 2018</a><br><a href="#">CROI 2018, Abstract 71, Webcast</a>                                                                                               |
| <b>DRONE:</b> Impact of starting a dolutegravir-based regimen on HIV-1 proviral DNA reservoir of treatment naïve and experienced patients | <a href="#">NCT02370979</a>  | University Hospital, Strasbourg, France                    | Phase IV   | N/A                                                                                                                                                                                            |
| <b>LEOPARD:</b> Latency and early neonatal provision of antiretroviral drugs clinical trial                                               | <a href="#">NCT02431975</a>  | Columbia University                                        | Phase IV   | <a href="#">PLoS Pathog. 2022;18(8):e1010751</a><br><a href="#">CID, ciab586</a><br><a href="#">J Clin Med. 2021 May 12;10(10):2074.</a><br><a href="#">EClinicalMedicine 18 (2020) 100241</a> |
| <b>P25-INACTION:</b> Implication for strategies of long term control of viral replication in patients with primary HIV infection          | <a href="#">NCT04225325</a>  | Adriano Lazzarin, MD                                       | Phase IV   | <a href="#">JAA. 64(2):107200.</a><br><a href="#">J Med Virol. 2023 Sep;95(9):e29114.</a><br><a href="#">EACS 2021, Abstract BPD4/3</a>                                                        |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                              | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                                                  | Phase        | Published/Presented Data                                                                                                                     |
|--------------------------------------------------------------------------------------------------------------------|------------------------------|-------------------------------------------------------------------------------------------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| <b>TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)</b>                                                           |                              |                                                                                           |              |                                                                                                                                              |
| <b>ANRS 147 OPTIPRIM:</b> Optimization of primary HIV-1 infection treatment                                        | <a href="#">NCT01033760</a>  | Inserm-ANRS                                                                               | Phase III    | <a href="#">PLoS One. 2013; 8(5): e64219.</a><br><a href="#">PLoS One. 2013; 8(3): e59767</a><br>IAS 2013, <a href="#">Abstract WEAB0101</a> |
| <b>maraviroc</b>                                                                                                   | <a href="#">NCT00808002</a>  | Germans Trias i Pujol Hospital                                                            | Phase III    | <a href="#">AIDS. 2014 Jan 28;28(3):325–34</a>                                                                                               |
| <b>raltegravir + maraviroc</b>                                                                                     | <a href="#">NCT00935480</a>  | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer                               | Phase III    | N/A                                                                                                                                          |
| <b>raltegravir</b>                                                                                                 | <a href="#">NCT00554398</a>  | Germans Trias i Pujol Hospital                                                            | Phase III    | <a href="#">Antivir Ther. 2012;17(2):355–64</a>                                                                                              |
| <b>tenofovir/emtricitabine + dolutegravir or tenofovir/emtricitabine + darunavir/cobicistat</b>                    | <a href="#">NCT02987530</a>  | Inserm/ANRS                                                                               | Phase III    | N/A                                                                                                                                          |
| <b>VIRECURE:</b> Impact of extremely early ART to reduce viral reservoir & induce functional cure of HIV infection | <a href="#">NCT02588820</a>  | David Garcia Cinca, Hospital Clinic of Barcelona                                          | Phase III    | EACS 2019, <a href="#">Abstract PE38/2</a>                                                                                                   |
| Intense acute infection study                                                                                      | <a href="#">NCT01154673</a>  | University of Toronto                                                                     | Phase II/III | <a href="#">J Virol. 93(6): e01832-18.</a><br><a href="#">OFID 2(4): ofv138.</a>                                                             |
| <b>EDIT:</b> Effect of dolutegravir intensification on HIV-1 reservoirs                                            | <a href="#">NCT05351684</a>  | University of Liege                                                                       | Phase II     | CROI 2023, <a href="#">Abstract 429</a>                                                                                                      |
| <b>maraviroc</b>                                                                                                   | <a href="#">NCT00795444</a>  | Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal/Pfizer | Phase II     | <a href="#">AIDS. 2013 Aug 24; 27(13):2081-8.</a><br><a href="#">PLoS One. 2011; 6(12):e27864</a>                                            |
| <b>peginterferon alfa-2a (Pegasys)</b>                                                                             | <a href="#">NCT00594880</a>  | Wistar Institute                                                                          | Phase II     | <a href="#">EBioMedicine. 2020 Aug 19;59:102945.</a><br><a href="#">J Infect Dis. 2013 Jan 15; 207(2): 213–222</a>                           |
| <b>peginterferon alfa-2b</b>                                                                                       | <a href="#">NCT01935089</a>  | University of Pennsylvania/Wistar Institute                                               | Phase II     | <a href="#">AIDS Res Hum Retroviruses. 2020 Dec 15.</a><br>CROI 2017, <a href="#">Poster abstract 326</a>                                    |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)

# Research Toward a Cure July 16, 2025

**Table 3. Completed Studies (Cont.)**

| Trial                                                                                                                   | Trial Registry Identifier(s) | Manufacturer/ Sponsor(s)                                                           | Phase      | Published/Presented Data                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------|------------------------------|------------------------------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)</b>                                                                |                              |                                                                                    |            |                                                                                                                                                                              |
| <b>peginterferon alfa-2b</b>                                                                                            | <a href="#">NCT02227277</a>  | Wistar Institute                                                                   | Phase II   | HIV Persistence Workshop 2019, Abstract PP 4.1 (see <a href="#">abstract book</a> ) CROI 2019, <a href="#">Abstract 136</a> , <a href="#">Webcast</a>                        |
| <b>raltegravir</b>                                                                                                      | <a href="#">NCT00520897</a>  | Canadian Immunodeficiency Research Collaborative                                   | Phase II   | <a href="#">AIDS. 2012 Jan 14;26(2):167-74</a>                                                                                                                               |
| <b>raltegravir</b>                                                                                                      | <a href="#">NCT00807443</a>  | Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal | Phase II   | <a href="#">AIDS. 2012 Sep 24;26(15):1885-94</a>                                                                                                                             |
| Viral suppression after analytic treatment interruption in Thai patients who initiated HAART during acute HIV infection | <a href="#">NCT02614950</a>  | South East Asia Research Collaboration with Hawaii                                 | Phase II   | <a href="#">Clin Infect Dis. 73(7):e1885-e1892.</a><br><a href="#">Nat Med. 2018 Jul;24(7):923-926.</a><br>CROI 2017, <a href="#">Abstract 124</a> , <a href="#">Webcast</a> |
| <b>alpha interferon intensification</b>                                                                                 | <a href="#">NCT01295515</a>  | NIAID                                                                              | Phase I/II | N/A                                                                                                                                                                          |
| <b>indinavir + zidovudine + lamivudine + nevirapine</b>                                                                 | <a href="#">NCT00001644</a>  | NIAID                                                                              | Phase I    | N/A                                                                                                                                                                          |

Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.

For the most up-to-date version, visit: <http://www.treatmentactiongroup.org/cure/trials>. Please send updates, corrections, or suggestions to Richard Jefferys at [richard.jefferys@treatmentactiongroup.org](mailto:richard.jefferys@treatmentactiongroup.org)